


<!DOCTYPE html>
<html lang="en-CA">
  <head>
    <title>
    Benzodiazepine Use in Older Adults |     Centre for Effective Practice - Digital Tools        </title>
  <meta charset="UTF-8" />
  <meta name="viewport" content="width=device-width" />
  <meta name="theme-color" content="#999999" />
  <link href="https://fonts.googleapis.com/css?family=Montserrat:500,500i,700,700i|Open+Sans:400,400i,700,700i&display=swap" rel="stylesheet">
  <meta name='robots' content='noindex, nofollow' />
	<style>img:is([sizes="auto" i], [sizes^="auto," i]) { contain-intrinsic-size: 3000px 1500px }</style>
	<link rel='dns-prefetch' href='//a.omappapi.com' />
<link rel='dns-prefetch' href='//www.googletagmanager.com' />
		<!-- This site uses the Google Analytics by MonsterInsights plugin v9.5.3 - Using Analytics tracking - https://www.monsterinsights.com/ -->
							<script src="//www.googletagmanager.com/gtag/js?id=G-G1F4BDXK7E"  data-cfasync="false" data-wpfc-render="false" type="text/javascript" async></script>
			<script data-cfasync="false" data-wpfc-render="false" type="text/javascript">
				var mi_version = '9.5.3';
				var mi_track_user = true;
				var mi_no_track_reason = '';
								var MonsterInsightsDefaultLocations = {"page_location":"https:\/\/tools.cep.health\/tool\/managing-benzodiazepine-use-in-older-adults\/"};
				if ( typeof MonsterInsightsPrivacyGuardFilter === 'function' ) {
					var MonsterInsightsLocations = (typeof MonsterInsightsExcludeQuery === 'object') ? MonsterInsightsPrivacyGuardFilter( MonsterInsightsExcludeQuery ) : MonsterInsightsPrivacyGuardFilter( MonsterInsightsDefaultLocations );
				} else {
					var MonsterInsightsLocations = (typeof MonsterInsightsExcludeQuery === 'object') ? MonsterInsightsExcludeQuery : MonsterInsightsDefaultLocations;
				}

								var disableStrs = [
										'ga-disable-G-G1F4BDXK7E',
									];

				/* Function to detect opted out users */
				function __gtagTrackerIsOptedOut() {
					for (var index = 0; index < disableStrs.length; index++) {
						if (document.cookie.indexOf(disableStrs[index] + '=true') > -1) {
							return true;
						}
					}

					return false;
				}

				/* Disable tracking if the opt-out cookie exists. */
				if (__gtagTrackerIsOptedOut()) {
					for (var index = 0; index < disableStrs.length; index++) {
						window[disableStrs[index]] = true;
					}
				}

				/* Opt-out function */
				function __gtagTrackerOptout() {
					for (var index = 0; index < disableStrs.length; index++) {
						document.cookie = disableStrs[index] + '=true; expires=Thu, 31 Dec 2099 23:59:59 UTC; path=/';
						window[disableStrs[index]] = true;
					}
				}

				if ('undefined' === typeof gaOptout) {
					function gaOptout() {
						__gtagTrackerOptout();
					}
				}
								window.dataLayer = window.dataLayer || [];

				window.MonsterInsightsDualTracker = {
					helpers: {},
					trackers: {},
				};
				if (mi_track_user) {
					function __gtagDataLayer() {
						dataLayer.push(arguments);
					}

					function __gtagTracker(type, name, parameters) {
						if (!parameters) {
							parameters = {};
						}

						if (parameters.send_to) {
							__gtagDataLayer.apply(null, arguments);
							return;
						}

						if (type === 'event') {
														parameters.send_to = monsterinsights_frontend.v4_id;
							var hookName = name;
							if (typeof parameters['event_category'] !== 'undefined') {
								hookName = parameters['event_category'] + ':' + name;
							}

							if (typeof MonsterInsightsDualTracker.trackers[hookName] !== 'undefined') {
								MonsterInsightsDualTracker.trackers[hookName](parameters);
							} else {
								__gtagDataLayer('event', name, parameters);
							}
							
						} else {
							__gtagDataLayer.apply(null, arguments);
						}
					}

					__gtagTracker('js', new Date());
					__gtagTracker('set', {
						'developer_id.dZGIzZG': true,
											});
					if ( MonsterInsightsLocations.page_location ) {
						__gtagTracker('set', MonsterInsightsLocations);
					}
										__gtagTracker('config', 'G-G1F4BDXK7E', {"forceSSL":"true","link_attribution":"true","page_path":location.pathname + location.search + location.hash} );
															window.gtag = __gtagTracker;										(function () {
						/* https://developers.google.com/analytics/devguides/collection/analyticsjs/ */
						/* ga and __gaTracker compatibility shim. */
						var noopfn = function () {
							return null;
						};
						var newtracker = function () {
							return new Tracker();
						};
						var Tracker = function () {
							return null;
						};
						var p = Tracker.prototype;
						p.get = noopfn;
						p.set = noopfn;
						p.send = function () {
							var args = Array.prototype.slice.call(arguments);
							args.unshift('send');
							__gaTracker.apply(null, args);
						};
						var __gaTracker = function () {
							var len = arguments.length;
							if (len === 0) {
								return;
							}
							var f = arguments[len - 1];
							if (typeof f !== 'object' || f === null || typeof f.hitCallback !== 'function') {
								if ('send' === arguments[0]) {
									var hitConverted, hitObject = false, action;
									if ('event' === arguments[1]) {
										if ('undefined' !== typeof arguments[3]) {
											hitObject = {
												'eventAction': arguments[3],
												'eventCategory': arguments[2],
												'eventLabel': arguments[4],
												'value': arguments[5] ? arguments[5] : 1,
											}
										}
									}
									if ('pageview' === arguments[1]) {
										if ('undefined' !== typeof arguments[2]) {
											hitObject = {
												'eventAction': 'page_view',
												'page_path': arguments[2],
											}
										}
									}
									if (typeof arguments[2] === 'object') {
										hitObject = arguments[2];
									}
									if (typeof arguments[5] === 'object') {
										Object.assign(hitObject, arguments[5]);
									}
									if ('undefined' !== typeof arguments[1].hitType) {
										hitObject = arguments[1];
										if ('pageview' === hitObject.hitType) {
											hitObject.eventAction = 'page_view';
										}
									}
									if (hitObject) {
										action = 'timing' === arguments[1].hitType ? 'timing_complete' : hitObject.eventAction;
										hitConverted = mapArgs(hitObject);
										__gtagTracker('event', action, hitConverted);
									}
								}
								return;
							}

							function mapArgs(args) {
								var arg, hit = {};
								var gaMap = {
									'eventCategory': 'event_category',
									'eventAction': 'event_action',
									'eventLabel': 'event_label',
									'eventValue': 'event_value',
									'nonInteraction': 'non_interaction',
									'timingCategory': 'event_category',
									'timingVar': 'name',
									'timingValue': 'value',
									'timingLabel': 'event_label',
									'page': 'page_path',
									'location': 'page_location',
									'title': 'page_title',
									'referrer' : 'page_referrer',
								};
								for (arg in args) {
																		if (!(!args.hasOwnProperty(arg) || !gaMap.hasOwnProperty(arg))) {
										hit[gaMap[arg]] = args[arg];
									} else {
										hit[arg] = args[arg];
									}
								}
								return hit;
							}

							try {
								f.hitCallback();
							} catch (ex) {
							}
						};
						__gaTracker.create = newtracker;
						__gaTracker.getByName = newtracker;
						__gaTracker.getAll = function () {
							return [];
						};
						__gaTracker.remove = noopfn;
						__gaTracker.loaded = true;
						window['__gaTracker'] = __gaTracker;
					})();
									} else {
										console.log("");
					(function () {
						function __gtagTracker() {
							return null;
						}

						window['__gtagTracker'] = __gtagTracker;
						window['gtag'] = __gtagTracker;
					})();
									}
			</script>
				<!-- / Google Analytics by MonsterInsights -->
		<link rel='stylesheet' id='wp-block-library-css' href='https://tools.cep.health/wp-includes/css/dist/block-library/style.min.css?ver=6.8.2' media='all' />
<style id='classic-theme-styles-inline-css' type='text/css'>
/*! This file is auto-generated */
.wp-block-button__link{color:#fff;background-color:#32373c;border-radius:9999px;box-shadow:none;text-decoration:none;padding:calc(.667em + 2px) calc(1.333em + 2px);font-size:1.125em}.wp-block-file__button{background:#32373c;color:#fff;text-decoration:none}
</style>
<style id='global-styles-inline-css' type='text/css'>
:root{--wp--preset--aspect-ratio--square: 1;--wp--preset--aspect-ratio--4-3: 4/3;--wp--preset--aspect-ratio--3-4: 3/4;--wp--preset--aspect-ratio--3-2: 3/2;--wp--preset--aspect-ratio--2-3: 2/3;--wp--preset--aspect-ratio--16-9: 16/9;--wp--preset--aspect-ratio--9-16: 9/16;--wp--preset--color--black: #000000;--wp--preset--color--cyan-bluish-gray: #abb8c3;--wp--preset--color--white: #ffffff;--wp--preset--color--pale-pink: #f78da7;--wp--preset--color--vivid-red: #cf2e2e;--wp--preset--color--luminous-vivid-orange: #ff6900;--wp--preset--color--luminous-vivid-amber: #fcb900;--wp--preset--color--light-green-cyan: #7bdcb5;--wp--preset--color--vivid-green-cyan: #00d084;--wp--preset--color--pale-cyan-blue: #8ed1fc;--wp--preset--color--vivid-cyan-blue: #0693e3;--wp--preset--color--vivid-purple: #9b51e0;--wp--preset--gradient--vivid-cyan-blue-to-vivid-purple: linear-gradient(135deg,rgba(6,147,227,1) 0%,rgb(155,81,224) 100%);--wp--preset--gradient--light-green-cyan-to-vivid-green-cyan: linear-gradient(135deg,rgb(122,220,180) 0%,rgb(0,208,130) 100%);--wp--preset--gradient--luminous-vivid-amber-to-luminous-vivid-orange: linear-gradient(135deg,rgba(252,185,0,1) 0%,rgba(255,105,0,1) 100%);--wp--preset--gradient--luminous-vivid-orange-to-vivid-red: linear-gradient(135deg,rgba(255,105,0,1) 0%,rgb(207,46,46) 100%);--wp--preset--gradient--very-light-gray-to-cyan-bluish-gray: linear-gradient(135deg,rgb(238,238,238) 0%,rgb(169,184,195) 100%);--wp--preset--gradient--cool-to-warm-spectrum: linear-gradient(135deg,rgb(74,234,220) 0%,rgb(151,120,209) 20%,rgb(207,42,186) 40%,rgb(238,44,130) 60%,rgb(251,105,98) 80%,rgb(254,248,76) 100%);--wp--preset--gradient--blush-light-purple: linear-gradient(135deg,rgb(255,206,236) 0%,rgb(152,150,240) 100%);--wp--preset--gradient--blush-bordeaux: linear-gradient(135deg,rgb(254,205,165) 0%,rgb(254,45,45) 50%,rgb(107,0,62) 100%);--wp--preset--gradient--luminous-dusk: linear-gradient(135deg,rgb(255,203,112) 0%,rgb(199,81,192) 50%,rgb(65,88,208) 100%);--wp--preset--gradient--pale-ocean: linear-gradient(135deg,rgb(255,245,203) 0%,rgb(182,227,212) 50%,rgb(51,167,181) 100%);--wp--preset--gradient--electric-grass: linear-gradient(135deg,rgb(202,248,128) 0%,rgb(113,206,126) 100%);--wp--preset--gradient--midnight: linear-gradient(135deg,rgb(2,3,129) 0%,rgb(40,116,252) 100%);--wp--preset--font-size--small: 13px;--wp--preset--font-size--medium: 20px;--wp--preset--font-size--large: 36px;--wp--preset--font-size--x-large: 42px;--wp--preset--spacing--20: 0.44rem;--wp--preset--spacing--30: 0.67rem;--wp--preset--spacing--40: 1rem;--wp--preset--spacing--50: 1.5rem;--wp--preset--spacing--60: 2.25rem;--wp--preset--spacing--70: 3.38rem;--wp--preset--spacing--80: 5.06rem;--wp--preset--shadow--natural: 6px 6px 9px rgba(0, 0, 0, 0.2);--wp--preset--shadow--deep: 12px 12px 50px rgba(0, 0, 0, 0.4);--wp--preset--shadow--sharp: 6px 6px 0px rgba(0, 0, 0, 0.2);--wp--preset--shadow--outlined: 6px 6px 0px -3px rgba(255, 255, 255, 1), 6px 6px rgba(0, 0, 0, 1);--wp--preset--shadow--crisp: 6px 6px 0px rgba(0, 0, 0, 1);}:where(.is-layout-flex){gap: 0.5em;}:where(.is-layout-grid){gap: 0.5em;}body .is-layout-flex{display: flex;}.is-layout-flex{flex-wrap: wrap;align-items: center;}.is-layout-flex > :is(*, div){margin: 0;}body .is-layout-grid{display: grid;}.is-layout-grid > :is(*, div){margin: 0;}:where(.wp-block-columns.is-layout-flex){gap: 2em;}:where(.wp-block-columns.is-layout-grid){gap: 2em;}:where(.wp-block-post-template.is-layout-flex){gap: 1.25em;}:where(.wp-block-post-template.is-layout-grid){gap: 1.25em;}.has-black-color{color: var(--wp--preset--color--black) !important;}.has-cyan-bluish-gray-color{color: var(--wp--preset--color--cyan-bluish-gray) !important;}.has-white-color{color: var(--wp--preset--color--white) !important;}.has-pale-pink-color{color: var(--wp--preset--color--pale-pink) !important;}.has-vivid-red-color{color: var(--wp--preset--color--vivid-red) !important;}.has-luminous-vivid-orange-color{color: var(--wp--preset--color--luminous-vivid-orange) !important;}.has-luminous-vivid-amber-color{color: var(--wp--preset--color--luminous-vivid-amber) !important;}.has-light-green-cyan-color{color: var(--wp--preset--color--light-green-cyan) !important;}.has-vivid-green-cyan-color{color: var(--wp--preset--color--vivid-green-cyan) !important;}.has-pale-cyan-blue-color{color: var(--wp--preset--color--pale-cyan-blue) !important;}.has-vivid-cyan-blue-color{color: var(--wp--preset--color--vivid-cyan-blue) !important;}.has-vivid-purple-color{color: var(--wp--preset--color--vivid-purple) !important;}.has-black-background-color{background-color: var(--wp--preset--color--black) !important;}.has-cyan-bluish-gray-background-color{background-color: var(--wp--preset--color--cyan-bluish-gray) !important;}.has-white-background-color{background-color: var(--wp--preset--color--white) !important;}.has-pale-pink-background-color{background-color: var(--wp--preset--color--pale-pink) !important;}.has-vivid-red-background-color{background-color: var(--wp--preset--color--vivid-red) !important;}.has-luminous-vivid-orange-background-color{background-color: var(--wp--preset--color--luminous-vivid-orange) !important;}.has-luminous-vivid-amber-background-color{background-color: var(--wp--preset--color--luminous-vivid-amber) !important;}.has-light-green-cyan-background-color{background-color: var(--wp--preset--color--light-green-cyan) !important;}.has-vivid-green-cyan-background-color{background-color: var(--wp--preset--color--vivid-green-cyan) !important;}.has-pale-cyan-blue-background-color{background-color: var(--wp--preset--color--pale-cyan-blue) !important;}.has-vivid-cyan-blue-background-color{background-color: var(--wp--preset--color--vivid-cyan-blue) !important;}.has-vivid-purple-background-color{background-color: var(--wp--preset--color--vivid-purple) !important;}.has-black-border-color{border-color: var(--wp--preset--color--black) !important;}.has-cyan-bluish-gray-border-color{border-color: var(--wp--preset--color--cyan-bluish-gray) !important;}.has-white-border-color{border-color: var(--wp--preset--color--white) !important;}.has-pale-pink-border-color{border-color: var(--wp--preset--color--pale-pink) !important;}.has-vivid-red-border-color{border-color: var(--wp--preset--color--vivid-red) !important;}.has-luminous-vivid-orange-border-color{border-color: var(--wp--preset--color--luminous-vivid-orange) !important;}.has-luminous-vivid-amber-border-color{border-color: var(--wp--preset--color--luminous-vivid-amber) !important;}.has-light-green-cyan-border-color{border-color: var(--wp--preset--color--light-green-cyan) !important;}.has-vivid-green-cyan-border-color{border-color: var(--wp--preset--color--vivid-green-cyan) !important;}.has-pale-cyan-blue-border-color{border-color: var(--wp--preset--color--pale-cyan-blue) !important;}.has-vivid-cyan-blue-border-color{border-color: var(--wp--preset--color--vivid-cyan-blue) !important;}.has-vivid-purple-border-color{border-color: var(--wp--preset--color--vivid-purple) !important;}.has-vivid-cyan-blue-to-vivid-purple-gradient-background{background: var(--wp--preset--gradient--vivid-cyan-blue-to-vivid-purple) !important;}.has-light-green-cyan-to-vivid-green-cyan-gradient-background{background: var(--wp--preset--gradient--light-green-cyan-to-vivid-green-cyan) !important;}.has-luminous-vivid-amber-to-luminous-vivid-orange-gradient-background{background: var(--wp--preset--gradient--luminous-vivid-amber-to-luminous-vivid-orange) !important;}.has-luminous-vivid-orange-to-vivid-red-gradient-background{background: var(--wp--preset--gradient--luminous-vivid-orange-to-vivid-red) !important;}.has-very-light-gray-to-cyan-bluish-gray-gradient-background{background: var(--wp--preset--gradient--very-light-gray-to-cyan-bluish-gray) !important;}.has-cool-to-warm-spectrum-gradient-background{background: var(--wp--preset--gradient--cool-to-warm-spectrum) !important;}.has-blush-light-purple-gradient-background{background: var(--wp--preset--gradient--blush-light-purple) !important;}.has-blush-bordeaux-gradient-background{background: var(--wp--preset--gradient--blush-bordeaux) !important;}.has-luminous-dusk-gradient-background{background: var(--wp--preset--gradient--luminous-dusk) !important;}.has-pale-ocean-gradient-background{background: var(--wp--preset--gradient--pale-ocean) !important;}.has-electric-grass-gradient-background{background: var(--wp--preset--gradient--electric-grass) !important;}.has-midnight-gradient-background{background: var(--wp--preset--gradient--midnight) !important;}.has-small-font-size{font-size: var(--wp--preset--font-size--small) !important;}.has-medium-font-size{font-size: var(--wp--preset--font-size--medium) !important;}.has-large-font-size{font-size: var(--wp--preset--font-size--large) !important;}.has-x-large-font-size{font-size: var(--wp--preset--font-size--x-large) !important;}
:where(.wp-block-post-template.is-layout-flex){gap: 1.25em;}:where(.wp-block-post-template.is-layout-grid){gap: 1.25em;}
:where(.wp-block-columns.is-layout-flex){gap: 2em;}:where(.wp-block-columns.is-layout-grid){gap: 2em;}
:root :where(.wp-block-pullquote){font-size: 1.5em;line-height: 1.6;}
</style>
<link rel='stylesheet' id='studio123_styles-css' href='https://tools.cep.health/wp-content/themes/cep-tools/style.min.css?ver=1743561782' media='all' />
<link rel='stylesheet' id='glossary-hint-css' href='https://tools.cep.health/wp-content/plugins/glossary-by-codeat/assets/css/tooltip-classic.css?ver=2.3.5' media='all' />
<script type="text/javascript" src="https://tools.cep.health/wp-content/plugins/google-analytics-for-wordpress/assets/js/frontend-gtag.min.js?ver=9.5.3" id="monsterinsights-frontend-script-js" async="async" data-wp-strategy="async"></script>
<script data-cfasync="false" data-wpfc-render="false" type="text/javascript" id='monsterinsights-frontend-script-js-extra'>/* <![CDATA[ */
var monsterinsights_frontend = {"js_events_tracking":"true","download_extensions":"doc,pdf,ppt,zip,xls,docx,pptx,xlsx","inbound_paths":"[{\"path\":\"\\\/go\\\/\",\"label\":\"affiliate\"},{\"path\":\"\\\/recommend\\\/\",\"label\":\"affiliate\"}]","home_url":"https:\/\/tools.cep.health","hash_tracking":"true","v4_id":"G-G1F4BDXK7E"};/* ]]> */
</script>

<!-- Google tag (gtag.js) snippet added by Site Kit -->

<!-- Google Analytics snippet added by Site Kit -->
<script type="text/javascript" src="https://www.googletagmanager.com/gtag/js?id=GT-MBGGM43" id="google_gtagjs-js" async></script>
<script type="text/javascript" id="google_gtagjs-js-after">
/* <![CDATA[ */
window.dataLayer = window.dataLayer || [];function gtag(){dataLayer.push(arguments);}
gtag("set","linker",{"domains":["tools.cep.health"]});
gtag("js", new Date());
gtag("set", "developer_id.dZTNiMT", true);
gtag("config", "GT-MBGGM43");
/* ]]> */
</script>

<!-- End Google tag (gtag.js) snippet added by Site Kit -->
<script type="text/javascript" src="https://tools.cep.health/wp-content/themes/cep-tools/js/jquery.min.js" id="jquery-js"></script>
<script type="text/javascript" src="https://tools.cep.health/wp-content/themes/cep-tools/js/jquery-migrate.min.js" id="jquery-migrate-js"></script>
<link rel="https://api.w.org/" href="https://tools.cep.health/wp-json/" /><link rel="alternate" title="JSON" type="application/json" href="https://tools.cep.health/wp-json/wp/v2/tools/12552" /><link rel="alternate" title="oEmbed (JSON)" type="application/json+oembed" href="https://tools.cep.health/wp-json/oembed/1.0/embed?url=https%3A%2F%2Ftools.cep.health%2Ftool%2Fmanaging-benzodiazepine-use-in-older-adults%2F" />
<link rel="alternate" title="oEmbed (XML)" type="text/xml+oembed" href="https://tools.cep.health/wp-json/oembed/1.0/embed?url=https%3A%2F%2Ftools.cep.health%2Ftool%2Fmanaging-benzodiazepine-use-in-older-adults%2F&#038;format=xml" />
<meta name="generator" content="Site Kit by Google 1.155.0" />
<!-- Google Tag Manager snippet added by Site Kit -->
<script type="text/javascript">
/* <![CDATA[ */

			( function( w, d, s, l, i ) {
				w[l] = w[l] || [];
				w[l].push( {'gtm.start': new Date().getTime(), event: 'gtm.js'} );
				var f = d.getElementsByTagName( s )[0],
					j = d.createElement( s ), dl = l != 'dataLayer' ? '&l=' + l : '';
				j.async = true;
				j.src = 'https://www.googletagmanager.com/gtm.js?id=' + i + dl;
				f.parentNode.insertBefore( j, f );
			} )( window, document, 'script', 'dataLayer', 'GTM-WLFDZV' );
			
/* ]]> */
</script>

<!-- End Google Tag Manager snippet added by Site Kit -->
<link rel="icon" href="https://tools.cep.health/wp-content/uploads/2019/10/cropped-Frame-36-1-32x32.png" sizes="32x32" />
<link rel="icon" href="https://tools.cep.health/wp-content/uploads/2019/10/cropped-Frame-36-1-192x192.png" sizes="192x192" />
<link rel="apple-touch-icon" href="https://tools.cep.health/wp-content/uploads/2019/10/cropped-Frame-36-1-180x180.png" />
<meta name="msapplication-TileImage" content="https://tools.cep.health/wp-content/uploads/2019/10/cropped-Frame-36-1-270x270.png" />
		<style type="text/css" id="wp-custom-css">
			.m0 {margin-top:0; margin-bottom: 0}		</style>
		<!--- Error: No Google analytics ID found. Go to Site Options > Analytics to enter your ID. ---><script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({"gtm.start":new Date().getTime(),event:"gtm.js"});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!="dataLayer"?"&l="+l:"";j.async=true;j.src="https://www.googletagmanager.com/gtm.js?id="+i+dl;f.parentNode.insertBefore(j,f);})(window,document,"script","dataLayer","GTM-K6HPX8H");</script>  </head>
  <body class="wp-singular tools-template-default single single-tools postid-12552 wp-theme-cep-tools managing-benzodiazepine-use-in-older-adults">

      <!-- Google Tag Manager (noscript) -->
    <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-K6HPX8H"
    height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
    <!-- End Google Tag Manager (noscript) -->

    <header>
      <div class="container">
        <div class="columns is-flex is-gapless">
          <div class="column">
            <a class="logo" target="_self" href="https://cep.health/tools" data-wpel-link="external" rel="external noopener noreferrer">
              <img src="https://tools.cep.health/wp-content/themes/cep-tools/img/logo.svg" alt="Centre for Effective Practice - Digital Tools" />
            </a>
          </div>
        </div>
      </div>
    </header>

<main>
  	<section class="section--impact_area">
    <div class="container">
        <h1>Benzodiazepine Use in Older Adults</h1>
                    <p class="last-updated"><i class="icon icon-clock-with-arrow"> </i>Last Updated: June 30, 2019</p>
                <ul class="links">
            <li>
                <button data-search-content class="button">Search Content&nbsp;&nbsp;<i class="icon icon-search"></i></a>
            </li>
                    </ul>
    </div>
</section>

		<section class="section--sections_listing" id="sections">

			
<div class="search-tool">
    <div class="search-tool-bar">
        <div class="search-wrapper">
            <div class="search-input-wrapper">
                <input data-search-tool-input type="search" autocomplete="off" placeholder="Enter search terms">
                <i class="icon icon-search"></i>
                <span class="search-no-results-found">No Results Found</span>
                <span class="search-result-count"><span class="current">0</span>/<span class="total">0</span></span>
            </div>
            <button data-search-previous disabled class="search-previous"><i class="icon icon-chevron-up"></i></button>
            <button data-search-next disabled class="search-next"><i class="icon icon-chevron-down"></i></button>
        </div>
        <button data-search-tool-close class="close"><i class="icon icon-close"></i></button>
    </div>
</div>
			<article class="block--paragraph  core-block" data-block-name="core/paragraph"><div class="container">
<p>This tool is designed to help primary care providers assess and discuss with their patients 65 years of age or older, the potential risks and benefits of benzodiazepines. This tool also contains steps to support primary care providers in safely discontinuing, starting or continuing to prescribe benzodiazepines for their older patients.</p>
</div></article>

<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h3 class="wp-block-heading">Potential risks and benefits of benzodiazepines</h3>
</div></article>

<article class="block--paragraph  core-block" data-block-name="core/paragraph"><div class="container">
<p>Benzodiazepines are not the preferred treatment for anxiety disorders, insomnia or panic disorder among older adults.<sup>1-4</sup> As patients age, their bodies respond to medications differently, and some medications become less safe than others.</p>
</div></article>

<article class="block--paragraph  core-block" data-block-name="core/paragraph"><div class="container">
<p>It is important to re-evaluate all medications as a patient approaches the age of 65. Re-evaluating the risks and benefits of concurrent medications is a routine part of medicine. It is particularly important to review the use of benzodiazepines, given the patient safety risks associated with the use of this medication in advanced age, as discussed in this tool.</p>
</div></article>


<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-9d6595d7 wp-block-columns-is-layout-flex">
<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow"><article class="block--background  core-block" data-block-name="cep/background"><div class="container">
<div class="wp-block-cep-background is-style-red-background"><article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h6 class="wp-block-heading"><strong>Potential Risks</strong></h6>
</div></article>

<article class="block--list  core-block" data-block-name="core/list"><div class="container">
<ul class="wp-block-list">
<li>Older adults have an increased sensitivity to benzodiazepines and decreased metabolism of long-acting agents</li>



<li>All benzodiazepines increase the risk of cognitive impairment, delirium, falls, fractures and motor vehicle accidents in older adults</li>



<li>Insomnia: NNH for any harm at 2 weeks = 6<sup>3</sup></li>
</ul>
</div></article></div>
</div></article></div>



<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow"><article class="block--background  core-block" data-block-name="cep/background"><div class="container">
<div class="wp-block-cep-background is-style-green-background"><article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h6 class="wp-block-heading"><strong>Potential Benefits</strong></h6>
</div></article>

<article class="block--list  core-block" data-block-name="core/list"><div class="container">
<ul class="wp-block-list">
<li>Anxiety disorders: NNT at 4-6 weeks = 7<sup>5</sup></li>



<li>Insomnia: NNT at 2 weeks = 13<sup>3</sup><article class="block--list  core-block" data-block-name="core/list"><div class="container">
<ul class="wp-block-list">
<li>34.2 additional minutes of sleep</li>



<li>0.60 less awakenings per night</li>
</ul>
</div></article></li>



<li>Panic disorder: NNT (timeframe unknown) = 5<sup>6</sup></li>
</ul>
</div></article>

<article class="block--paragraph  core-block" data-block-name="core/paragraph"><div class="container">
<p></p>
</div></article>

<article class="block--paragraph  core-block" data-block-name="core/paragraph"><div class="container">
<p></p>
</div></article></div>
</div></article></div>
</div>


<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h3 class="wp-block-heading">Determine whether a benzodiazepine is appropriate or problematic<sup>7</sup></h3>
</div></article>

<article class="block--text-with-icon ">  <div class="container">
    
        <div class="columns is-flex is-gapless">
          <div class="column is-2-mobile is-1">
            <div class="inner">
              <img decoding="async" src="https://tools.cep.health/wp-content/uploads/2019/10/Checkmark-Large-1.svg" />
            </div>
          </div>
          <div class="column is-10-mobile is-11">
            <div style="width: 45%; padding: 0 70px 0 0; float: left;">
<h6><strong>Identify patients opportunistically, when the patient:<sup>8, 9</sup></strong></h6>
<ul>
<li>Is 65 or over</li>
<li>Comes in for a preventative health exam</li>
<li>Comes in for a prescription renewal or refill</li>
<li>Has had a recent hospitalization</li>
<li>Has had a recent fall</li>
<li>Is admitted to long-term care</li>
<li>Presents with new cognitive concerns or early onset dementia</li>
<li>Reports driving difficulty or their family, caregivers or friends reports concerns</li>
<li>Demonstrates rapid escalation of medication use</li>
<li>Has an active substance use disorder that could trigger inappropriate or problematic use of benzodiazepines</li>
<li style="text-align: left;">Has a potential <span class="tooltip-wrapper"><span class="tooltip-parent">benzodiazepine use disorder<sup>13</sup></span><span class="tooltip-content">Possible indications of benzodiazepine use disorder:<br />
• Deteriorating function despite increasing dose<br />
• Dishonesty with respect to prescriptions (e.g. frequent reports of loss or theft of medications and/or routine early refill requests)<br />
• Involvement with law-enforcement<br />
• Non-oral route of administration<br />
• Active misuse of another substance<br />
• Diversion or other substance-dealing behaviour If patient presents with possible indications of a benzodiazepine use disorder, diagnose the patient using the DSM-5 criteria for Sedative, Hypnotic, or Anxiolytic Use Disorder.</span></span></li>
</ul>
</div>
<div style="width: 40%; padding: 0 10px 0 0; float: left;">
<h6><strong>Identify patients proactively:</strong></h6>
<ul>
<li><span style="font-size: 1.5rem;">Set EMR reminders or patient record flags as a reminder to review a patient’s benzodiazepine use during their next appointment.</span><sup>8</sup></li>
<li>Encourage patients to bring up their use of benzodiazepines during their next appointment:
<ul>
<li>mail or hand-out patient material to rostered patients ages 65 or over</li>
<li>put waiting room patient posters up or provide screening questions while patients wait for their appointments. This type of patient material is available from the <a style="font-size: 1.5rem; background-color: white;" href="https://link.cep.health/benzohtml1" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">Centre for Effective Practice</a><span style="font-size: 1.5rem;"> and the</span><a style="font-size: 1.5rem; background-color: white;" href="https://link.cep.health/benzohtml2" data-wpel-link="external" target="_blank" rel="external noopener noreferrer"> Canadian Deprescribing Network.</a></li>
</ul>
</li>
</ul>
</div>
          </div>
        </div>

      </div>
</article>

<article class="block--modal ">

<div class="outer">
  <div class="container">
    <div class="inner has-text-centered">
              <img decoding="async" src="https://tools.cep.health/wp-content/uploads/2019/10/talking-points.svg" alt="" />
                    <h6>Discuss their use of benzodiazepines</h6>
                          <a data-modal="6q76EG" class="button open-modal" href="#" data-id="6q76EG">Click to view</a>
          </div>
  </div>
</div>

  <div data-modal="6q76EG" class="modal">
    <div class="inner text">
      <div class="close-wrapper">
                <a href="" class="close" data-wpel-link="internal">Close</a>
      </div>
      <div class="container">
                <div class="content">
          
                          <h4>Discuss their use of benzodiazepines</h4>
                                      <h6><strong>Ask patients what they take the benzodiazepine for:</strong></h6>
<ul>
<li><strong> &#8220;</strong>What concerns did you originally start the benzodiazepine for?&#8221;<sup>10</sup></li>
<li>&#8220;Have the concerns that led to your initial benzodiazepine prescription changed?&#8221;<sup>10</sup></li>
</ul>
<h6><strong>Highlight the benefits versus risks of benzodiazepine use for older adults:</strong></h6>
<ul>
<li>&#8220;Although benzodiazepines sometimes offer small benefits in the short term, they stop working and become harder to wean from over time. Despite this, the serious side effects of taking benzodiazepines remain, such as cognitive impairment, delirium, falls, fractures and increased risk of motor vehicle accidents.&#8221;<sup>7</sup></li>
<li>&#8220;To maintain your independence, it is important to reduce or remove any medications that increase your risk of cognitive impairment, delirium, falls, fractures and motor vehicle accidents.&#8221;<sup>7</sup></li>
<li>&#8220;While taking a benzodiazepine you have an increased risk of side effects:
<ul>
<li>5 times higher risk of memory and concentration problems</li>
<li>4 times higher risk of daytime fatigue</li>
<li>2 times higher risk of falls and fractures (hip, wrist)</li>
<li>2 times higher risk of experiencing a motor vehicle accident&#8221;<sup>11</sup></li>
</ul>
</li>
<li>&#8220;The benzodiazepine may cause problems with your memory and concentration which could result in an assessment of your driving privileges.&#8221;<sup>9</sup></li>
</ul>
            
                  </div>
      </div>
    </div>
    <div class="overlay"></div>
</div></article>

<article class="block--text-with-icon ">  <div class="container">
    
        <div class="columns is-flex is-gapless">
          <div class="column is-2-mobile is-1">
            <div class="inner">
              <img decoding="async" src="https://tools.cep.health/wp-content/uploads/2020/05/info-icon.svg" />
            </div>
          </div>
          <div class="column is-10-mobile is-11">
            <h4><strong>Consider </strong><strong>benzodiazepine appropriateness</strong></h4>
<div style="width: 45%; padding: 0 70px 0 0; float: left;">
<h6>If the patient is taking/starting it for <strong>anxiety disorders / Insomnia / panic disorder</strong>:</h6>
<ul>
<li><a href="#discontinuing-benzodiazepines">Discontinuing Benzodiazepines</a></li>
<li><a href="#alternatives-to-benzodiazepines-for-anxiety">Alternatives to Benzodiazepines for Anxiety</a></li>
<li><a href="#alternatives-to-benzodiazepines-for-insomnia">Alternatives to Benzodiazepines for Insomnia</a></li>
<li><a href="#alternatives-to-benzodiazepines-for-panic-disorders">Alternatives to Benzodiazepines for Panic Disorders</a></li>
</ul>
</div>
<div style="width: 40%; padding: 0 10px 0 0; float: left;">
<h6>If the patient is taking/starting it for <strong>seizure disorders / alcohol withdrawal / Short-term use (&lt;4 weeks)</strong>:</h6>
<div class="page" title="Page 1">
<div class="layoutArea">
<div class="column">
<ul>
<li><a href="#starting-benzodiazepines">Starting Benzodiazepines</a></li>
<li><a href="#continuing-benzodiazepines">Continuing Benzodiazepines</a></li>
</ul>
</div>
</div>
</div>
</div>
          </div>
        </div>

      </div>
</article>			<div class="container has-text-right" style="padding: 0 0 1.5rem;">
				<div class="expand-all">
					<a href="#" data-expand-text="Expand All" data-collapse-text="Collapse All">Expand All</a>
				</div>
			</div>
			<div id="top-of-sections"></div>
							<section class="main-section" id="discontinuing-benzodiazepines" tabindex="-1">
					<div class="head">
						<div class="container">
							<h2 class="main-heading">
								Discontinuing Benzodiazepines								
							</h2>
							<div class="icon">
								<svg width="22" height="22" viewBox="0 0 22 22" fill="none" xmlns="http:/ /www.w3.org/2000/svg">
									<path fill-rule="evenodd" clip-rule="evenodd" d="M16 12H6V10H16V12Z" class="horizontal-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M10 16V6H12V16H10Z" class="vertical-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M11 20C15.9706 20 20 15.9706 20 11C20 6.02944 15.9706 2 11 2C6.02944 2 2 6.02944 2 11C2 15.9706 6.02944 20 11 20ZM11 22C17.0751 22 22 17.0751 22 11C22 4.92487 17.0751 0 11 0C4.92487 0 0 4.92487 0 11C0 17.0751 4.92487 22 11 22Z" class="outline" />
								</svg>
							</div>
						</div>
					</div>
					<div class="body">
						<div class="container">
							<article class="block--background  core-block" data-block-name="cep/background"><div class="container">
<div class="wp-block-cep-background is-style-red-background"><article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h3 class="wp-block-heading" id="beforetaper"><strong>Important information to collect before discontinuing benzodiazepines</strong></h3>
</div></article>

<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h6 class="wp-block-heading"><strong>Current dose and duration, including prn use of benzodiazepine</strong></h6>
</div></article>

<article class="block--list  core-block" data-block-name="core/list"><div class="container">
<ul class="wp-block-list">
<li>Discontinuation with no taper is possible if the benzodiazepine has been taken for &lt;3 weeks <sup>14</sup></li>



<li>Individuals taking the equivalent of ≥60mg diazepam daily (see <a href="#benzosON">Benzodiazepines available in Ontario</a>), or with a history of serious withdrawal reactions, should be hospitalized during acute withdrawal and tapering should be slower <sup>14</sup></li>
</ul>
</div></article>

<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h6 class="wp-block-heading"><strong>All prescribed and over-the-counter medications that the patient is currently taking</strong></h6>
</div></article>

<article class="block--list  core-block" data-block-name="core/list"><div class="container">
<ul class="wp-block-list">
<li>Including supplements, vitamins, and naturopathic treatments</li>
</ul>
</div></article>

<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h6 class="wp-block-heading"><strong>History of previous non-pharmacological and pharmacological alternatives tried for anxiety disorders, insomnia or panic disorder</strong></h6>
</div></article>

<article class="block--list  core-block" data-block-name="core/list"><div class="container">
<ul class="wp-block-list">
<li>Understand what the patient means by &#8220;tried&#8221; and consider if the duration &#8220;tried&#8221; is long enough to evaluate efficacy/side effects</li>



<li>An adequate trial of non- pharmacological and pharmacological alternatives is approximately 6-8 weeks</li>
</ul>
</div></article>

<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h6 class="wp-block-heading"><strong>Substance use history</strong></h6>
</div></article>

<article class="block--list  core-block" data-block-name="core/list"><div class="container">
<ul class="wp-block-list">
<li>E.g. alcohol, cannabinoids, caffeine, nicotine</li>
</ul>
</div></article>

<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h6 class="wp-block-heading"><strong>History of adverse events</strong></h6>
</div></article>

<article class="block--list  core-block" data-block-name="core/list"><div class="container">
<ul class="wp-block-list">
<li>E.g. delirium, dementia or cognitive impairment, falls, fractures or motor-vehicle accidents</li>
</ul>
</div></article>

<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h6 class="wp-block-heading"><strong>Baseline assessment of anxiety disorders, insomnia or panic disorder</strong></h6>
</div></article>

<article class="block--list  core-block" data-block-name="core/list"><div class="container">
<ul class="wp-block-list">
<li>Use validated assessment tools such as, <a href="https://link.cep.health/benzohtml3" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">GAD-7 and PHQ</a> (PHQ section 4 on panic disorder) <sup>15</sup>, and the <a href="https://link.cep.health/benzohtml4" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">Insomnia Severity Index.</a><sup>16</sup></li>
</ul>
</div></article></div>
</div></article>

<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h3 class="wp-block-heading" id="beforetaper"><strong>Tapering </strong>Steps</h3>
</div></article>

<article class="block--paragraph  core-block" data-block-name="core/paragraph"><div class="container">
<p>If taking a benzodiazepine is no longer appropriate for a patient, then use the following steps to help them taper off of the<br>medication or to a lower dose.</p>
</div></article>

<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h3 class="wp-block-heading" id="tapersteps">Step 1: Plan the taper</h3>
</div></article>

<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h6 class="wp-block-heading"><strong>Engage patients </strong></h6>
</div></article>

<article class="block--list  core-block" data-block-name="core/list"><div class="container">
<ul class="wp-block-list">
<li>In developing a clear plan for tapering, incorporating goals and preferences regarding benzodiazepine use.<sup>7</sup></li>



<li>Discuss a goal of discontinuation versus lowest possible dose<article class="block--list  core-block" data-block-name="core/list"><div class="container">
<ul class="wp-block-list">
<li>If a medication cannot be completely discontinued, a decrease in dose is still a win!</li>
</ul>
</div></article></li>



<li>Ensure patients know what is required of them (e.g. schedule for primary care provider visits and schedule for picking up prescriptions at designated pharmacy).</li>



<li>Reassure patients that they have control in the taper; taper can go as slow as they need and can be paused and adjusted as needed.</li>
</ul>
</div></article>

<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h6 class="wp-block-heading"><strong>Establish the formulation to be used for tapering</strong></h6>
</div></article>

<article class="block--list  core-block" data-block-name="core/list"><div class="container">
<ul class="wp-block-list">
<li>See <a href="#benzosON">Benzodiazepines available in Ontario</a> if switching patient to another benzodiazepine before tapering </li>



<li>There is insufficient evidence to support the use of one particular benzodiazepine over another (or for long&#8211;acting benzodiazepines vs. short-acting benzodiazepines) for a tapering schedule.<sup>7</sup> </li>



<li>Switching to long-acting benzodiazepines may be done (e.g. diazepam, clonazepam), but this has not shown to reduce the incidence of withdrawal symptoms or improve cessation rates more than tapering shorter-acting benzodiazepines.<sup>7</sup><article class="block--list  core-block" data-block-name="core/list"><div class="container">
<ul class="wp-block-list">
<li>Long-acting benzodiazepines do however offer advantages when tapering, including fewer rebound symptoms, constant drug levels and ease of formulation.<sup>14, 19, 20</sup> </li>



<li>To reduce the severity of withdrawal symptoms, keep a patient on a long-acting benzodiazepine for at least 2 months following a switch (from a short-acting benzodiazepine) and before initiating a taper from the long-acting benzodiazepine.<sup>14</sup></li>
</ul>
</div></article></li>
</ul>
</div></article>

<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h6 class="wp-block-heading"><strong>Establish the dosing interval</strong></h6>
</div></article>

<article class="block--list  core-block" data-block-name="core/list"><div class="container">
<ul class="wp-block-list">
<li>Scheduled doses are preferred over prn doses (to help with the withdrawal). </li>



<li>Keep the dosing interval constant (e.g. bid).</li>
</ul>
</div></article>


<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-9d6595d7 wp-block-columns-is-layout-flex">
<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow" style="flex-basis:66.66%"><article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h6 class="wp-block-heading"><strong>Establish the rate of the taper </strong></h6>
</div></article>

<article class="block--list  core-block" data-block-name="core/list"><div class="container">
<ul class="wp-block-list">
<li>Based on the patient’s health and preferences, as well as formulations available for the current benzodiazepine <a href="#benzosON">see Benzodiazepines available in Ontario</a>.</li>



<li>For older adults, it is recommended to taper the benzodiazepine dose slowly: <strong>25% reduction every 2 weeks and then a slower taper of 12.5% every 2 weeks near the end.</strong><sup>7</sup> </li>



<li>For long-acting benzodiazepines taper by no more than diazepam 5mg or clonazepam 0.25mg equivalent/week.<sup>21</sup></li>
</ul>
</div></article></div>



<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow" style="flex-basis:33.33%"><article class="block--modal ">

<div class="outer">
  <div class="container">
    <div class="inner has-text-centered">
                    <h6>Alternative rates for tapering</h6>
                          <a data-modal="daomJk" class="button open-modal" href="#" data-id="daomJk">Click for details</a>
          </div>
  </div>
</div>

  <div data-modal="daomJk" class="modal">
    <div class="inner text">
      <div class="close-wrapper">
                <a href="" class="close" data-wpel-link="internal">Close</a>
      </div>
      <div class="container">
                <div class="content">
          
                          <h4>Alternative rates for tapering</h4>
                                      <ul>
<li>Taper by 10% every 1–2 weeks until 20% of the original dose is reached, then taper by 5% every 2–4 weeks<sup>14</sup></li>
<li>For those experiencing severe side effects or severe anxiety, consider a slower taper of 10% every 2 weeks<sup>14</sup></li>
<li>For those taking a benzodiazepine for panic disorder, taper the weekly dose by a maximum of 10% per week over a period of 2–4 months</li>
<li>For those who have been taking a long half-life benzodiazepine for only a short-term (e.g. up to 4 weeks of clorazepate or clonazepam), taper over 1 week</li>
<li>Alprazolam: for doses &lt;4mg/day, taper by no more than 0.5mg every 3 days or no more than 0.25mg every week<sup>14</sup></li>
<li>Alprazolam: for doses ≥4mg/day, even slower tapers over 3+ months are required (e.g. 0.5mg every 2–3 weeks, then slow to 0.25mg every 2–3 weeks when at 2mg/day)<sup>14</sup></li>
</ul>
<p><strong data-rich-text-format-boundary="true"> </strong></p>
            
                  </div>
      </div>
    </div>
    <div class="overlay"></div>
</div></article></div>
</div>


<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h6 class="wp-block-heading">Contact the patient’s pharmacy to discuss the tapering plan </h6>
</div></article>

<article class="block--list  core-block" data-block-name="core/list"><div class="container">
<ul class="wp-block-list">
<li>By phone and/or fax depending on what is feasible. </li>



<li>Discuss with the pharmacist any pill splitting or liquid formulations necessary to accommodate tapering doses as well as packaging options for older adults (e.g. dosette or blister pack). </li>



<li>For long-acting benzodiazepines&nbsp;instruct the pharmacist to dispense daily, weekly or every 2 weeks depending on the dose and patient reliability.<sup>21</sup></li>
</ul>
</div></article>

<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h3 class="wp-block-heading">Step 2: Consider adjunctive therapy</h3>
</div></article>

<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h6 class="wp-block-heading"><strong>Consider cognitive behaviour therapy </strong>to improve tapering success rates </h6>
</div></article>

<article class="block--list  core-block" data-block-name="core/list"><div class="container">
<ul class="wp-block-list">
<li>Cognitive behaviour therapy has the highest success rate for patients discontinuing benzodiazepines compared to usual care or other prescribing interventions (<a href="https://tools.cep.health/tool/managing-benzodiazepine-use-in-older-adults/#provider-and-patient-resources" data-wpel-link="internal">see Provider and Patients Resources</a>)<sup>7</sup>. </li>



<li>The use of pharmacological adjunctive agents has limited evidence to support success.</li>
</ul>
</div></article>

<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h3 class="wp-block-heading">Step 3. Initiate and monitor<sup>7,12</sup></h3>
</div></article>

<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h6 class="wp-block-heading"><strong>Decrease patient’s dose </strong></h6>
</div></article>

<article class="block--list  core-block" data-block-name="core/list"><div class="container">
<ul class="wp-block-list">
<li>By 25% (or decided upon rate) every 2 weeks until dose is close to end goal (discontinuation or lowest possible dose), then slow the dose reduction to 12.5% (or decided upon rate) every 2 weeks until the end goal is reached.<sup>7</sup></li>



<li>For long-acting benzodiazepines<sup> </sup>slow the pace of the taper once the dose is below 20mg of diazepam equivalent (e.g. 1–2 mg/week); adjust rate of taper according to patient&#8217;s symptoms.<sup>21</sup></li>
</ul>
</div></article>

<article class="block--modal ">

<div class="outer">
  <div class="container">
    <div class="inner has-text-centered">
              <img decoding="async" src="https://tools.cep.health/wp-content/uploads/2019/10/talking-points.svg" alt="" />
                    <h6>Talking tips</h6>
                          <a data-modal="ThF3TE" class="button open-modal" href="#" data-id="ThF3TE">Click to View</a>
          </div>
  </div>
</div>

  <div data-modal="ThF3TE" class="modal">
    <div class="inner text">
      <div class="close-wrapper">
                <a href="" class="close" data-wpel-link="internal">Close</a>
      </div>
      <div class="container">
                <div class="content">
          
                          <h4>Talking tips</h4>
                                      <ul>
<li>&#8220;There are more effective treatments than benzodiazepines for your [anxiety/ insomnia/panic disorder].&#8221; <sup>2, 17</sup></li>
<li>&#8220;Many people have successfully stopped taking their benzodiazepine — the majority of people can stop through tapering.&#8221; <sup>7, 18</sup></li>
</ul>
<p><strong>Ensure patients (and caregivers) are aware of withdrawal symptoms<sup>7</sup></strong></p>
<ul>
<li>&#8220;You may experience a night or two of worse sleep.”<sup>9</sup></li>
<li>&#8220;To reduce your risk of cognitive impairment, delirium, falls, fractures, and motor vehicle accidents, you might need to get through a few days/weeks of mild withdrawal symptoms.”<sup>9</sup></li>
</ul>
            
                  </div>
      </div>
    </div>
    <div class="overlay"></div>
</div></article>

<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h6 class="wp-block-heading">Monitor for expected benefits and withdrawal symptoms<strong><sup>7, 12</sup></strong></h6>
</div></article>

<article class="block--list  core-block" data-block-name="core/list"><div class="container">
<ul class="wp-block-list">
<li>Schedule follow-up appointments every 1-2 weeks (in-person or over the phone) to monitor for expected benefits as as well as adverse drug withdrawal symptoms and manage accordingly.<sup>7</sup> If a patient is at high risk of withdrawal symptoms, refer to a supervised setting during taper initiation.</li>



<li>Use validated assessment tools to assess withdrawal symptoms: <a href="https://link.cep.health/benzohtml40" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">Clinical Institute Withdrawal Assessment-Benzodiazepines</a><sup>23</sup> and/or <a href="https://link.cep.health/benzohtml8" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">The Benzodiazepine Withdrawal Symptom Questionnaire.</a><sup>24</sup></li>
</ul>
</div></article>


<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-9d6595d7 wp-block-columns-is-layout-flex">
<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow"><article class="block--paragraph  core-block" data-block-name="core/paragraph"><div class="container">
<p><strong>Expected benefits:</strong></p>
</div></article>

<article class="block--list  core-block" data-block-name="core/list"><div class="container">
<ul class="wp-block-list">
<li>Less daytime sedation</li>



<li>Improved cognition. Use validated assessment tools such as, the <a href="https://link.cep.health/benzohtml6" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">Montreal Cognitive Assessment</a><sup>.</sup><sup>22</sup></li>



<li>Fewer falls</li>



<li>Fewer fractures</li>



<li>Fewer motor vehicle accidents</li>



<li>Improved function</li>



<li>Fewer respiratory exacerbations</li>
</ul>
</div></article></div>



<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow"><article class="block--paragraph  core-block" data-block-name="core/paragraph"><div class="container">
<p><strong>Common withdrawal symptoms</strong>:</p>
</div></article>

<article class="block--list  core-block" data-block-name="core/list"><div class="container">
<ul class="wp-block-list">
<li>Rebound anxiety disorders and/or panic disorder. Use validated assessment tools such as, the <a href="https://link.cep.health/benzohtml3" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">GAD-7 and PHQ</a> (PHQ section 4 on panic disorder).<sup>15</sup></li>



<li>Rebound insomnia. Use a validated assessment tool such as, <a href="https://link.cep.health/benzohtml4" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">the Insomnia Severity Index</a>.<sup>16</sup></li>



<li>Irritability</li>



<li>Sweating</li>



<li>Gastrointestinal symptoms (i.e. diarrhea, abdominal cramps, nausea and vomiting)</li>



<li>Chills</li>



<li>Tremors</li>



<li>Dizziness</li>



<li>Visual distortion (patient should be told to see their primary care provider if they are experiencing visual distortion)</li>



<li>Tinnitus</li>
</ul>
</div></article></div>



<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow"><article class="block--paragraph  core-block" data-block-name="core/paragraph"><div class="container">
<p><strong>Severe withdrawal symptoms:*</strong></p>
</div></article>

<article class="block--list  core-block" data-block-name="core/list"><div class="container">
<ul class="wp-block-list">
<li>Agitation</li>



<li>Confusion</li>



<li>Disorientation</li>



<li>Depersonalization</li>



<li>Delirium</li>



<li>Seizures</li>



<li>Unstable vital signs</li>
</ul>
</div></article></div>
</div>


<article class="block--paragraph  core-block" data-block-name="core/paragraph"><div class="container">
<p style="font-size:12px">*Severe withdrawal symptoms do not appear to occur with tapering but have been reported rarely in patients stopping very high doses without tapering or who have underlying seizure disorders<sup>7</sup></p>
</div></article>

<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h6 class="wp-block-heading" id="withdrawal">Manage withdrawal symptom(s)</h6>
</div></article>

<article class="block--list  core-block" data-block-name="core/list"><div class="container">
<ul class="wp-block-list">
<li>If withdrawal symptoms are bothersome for a patient or if the taper is not going well, <strong>consider maintaining the current dose for an additional 1-2 weeks before attempting the next dose reduction, then continue to taper at a slower rate if appropriate</strong>.<sup>7</sup></li>



<li><strong>Currently, no medications are recommended or approved for the management of benzodiazepine withdrawal after long-term use.</strong><sup>27</sup> </li>
</ul>
</div></article>

<article class="block--table-with-icon "><div class="container">
        <div class="icon">
      <div class="inner" style="background-image:url(https://tools.cep.health/wp-content/uploads/2020/05/info-icon.svg);"></div>
    </div>
    <div class="table ">
          <div class="header">
              <div class="heading white">
          Pharmacotherapy symptom management        </div>
              <div class="body">
            <p><em>The following are temporary solutions (off-label) for acute relief of withdrawal symptoms that should be used with caution among older adults. These temporary solutions are based on clinical practice as quality evidence in this area is limited. If prescribing any of the following, use clinical judgment regarding the patient&#8217;s ability to tolerate these medications and closely monitor the patient.</em></p>
        </div>
              </div>
        <div class="body">
              <div class="row">
          
                                  <button data-content="zWhSJG" class="open-row">
                    <div class="heading">Rebound anxiety disorders, insomnia and/or panic disorder</div>
                    <span class="expand"><span class="text">Expand</span><span class="icon-plus"></span><span class="icon-minus"></span></span>
                  </button>
                                          <div class="body  collapsible" data-content="zWhSJG">
                <ul>
<li><a href="https://tools.cep.health/tool/managing-benzodiazepine-use-in-older-adults/#alternatives-to-benzodiazepines-for-anxiety" data-wpel-link="internal">Alternatives to Benzodiazepines for Anxiety</a></li>
<li><a href="https://tools.cep.health/tool/managing-benzodiazepine-use-in-older-adults/#alternatives-to-benzodiazepines-for-insomnia" data-wpel-link="internal">Alternatives to Benzodiazepines for Insomnia</a></li>
<li><a href="https://tools.cep.health/tool/managing-benzodiazepine-use-in-older-adults/#alternatives-to-benzodiazepines-for-panic-disorders" data-wpel-link="internal">Alternatives to Benzodiazepines for Panic Disorders</a></li>
</ul>

                          </div>
        
                                  <button data-content="yUrvGw" class="open-row">
                    <div class="heading">Sweating</div>
                    <span class="expand"><span class="text">Expand</span><span class="icon-plus"></span><span class="icon-minus"></span></span>
                  </button>
                                          <div class="body  collapsible" data-content="yUrvGw">
                <ul>
<li>Oxybutynin* 2.5–5mg bid prn (short-term use)</li>
<li>Ensure patient is well-hydrated</li>
</ul>
<p>&nbsp;</p>
<p><em>* Appears in 2019 AGS Beers Criteria® &#8211; the Beers Criteria is published by the American Geriatrics Society and is a list of potentially inappropriate medications in older adults<sup>28</sup></em></p>

                          </div>
        
                                  <button data-content="6XknE2" class="open-row">
                    <div class="heading">Diarrhea</div>
                    <span class="expand"><span class="text">Expand</span><span class="icon-plus"></span><span class="icon-minus"></span></span>
                  </button>
                                          <div class="body  collapsible" data-content="6XknE2">
                <ul>
<li>Stop stool softeners and/or laxatives (e.g. sennosides, docusate sodium, lactulose), if applicable</li>
<li>Loperamide (if necessary) 4mg STAT, then 2mg after each unformed stool up to a maximum of 16mg per day</li>
</ul>

                          </div>
        
                                  <button data-content="UGuYOM" class="open-row">
                    <div class="heading">Abdominal cramps, chills and tremors</div>
                    <span class="expand"><span class="text">Expand</span><span class="icon-plus"></span><span class="icon-minus"></span></span>
                  </button>
                                          <div class="body  collapsible" data-content="UGuYOM">
                <p>If BP &gt;90/50 mmHg, may give clonidine* 0.1mg (check BP and HR 1 hour later and if BP &lt;90/50, HR &lt;50 or dizziness, do not prescribe further); may titrate up to qid prn, then taper</p>
<p><em>* Appears in 2019 AGS Beers Criteria® &#8211; the Beers Criteria is published by the American Geriatrics Society and is a list of potentially inappropriate medications in older adults<sup>28</sup></em></p>

                          </div>
        
                                  <button data-content="RGlDLp" class="open-row">
                    <div class="heading">Nausea and vomiting</div>
                    <span class="expand"><span class="text">Expand</span><span class="icon-plus"></span><span class="icon-minus"></span></span>
                  </button>
                                          <div class="body  collapsible" data-content="RGlDLp">
                <ul>
<li>Dimenhydrinate* 25–50mg q4h prn •</li>
<li>Prochlorperazine* 5–10mg q6h prn</li>
<li>Haloperidol* 0.5–1mg q12h prn</li>
<li>Metoclopramide* 10mg q4–6h prn</li>
</ul>
<p><em>* Appears in 2019 AGS Beers Criteria® &#8211; the Beers Criteria is published by the American Geriatrics Society and is a list of potentially inappropriate medications in older adults<sup>28</sup></em></p>

                          </div>
              </div>
        </div>
  </div>

</div>
</article>

<article class="block--text-with-icon ">  <div class="container">
    
        <div class="columns is-flex is-gapless">
          <div class="column is-2-mobile is-1">
            <div class="inner">
              <img decoding="async" src="https://tools.cep.health/wp-content/uploads/2019/10/Eye.svg" />
            </div>
          </div>
          <div class="column is-10-mobile is-11">
            <h6>For additional examples of tapering approaches see <a href="https://link.cep.health/benzohtml5" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">The Ashton Manual</a>.</h6>
          </div>
        </div>

      </div>
</article>						</div>
					</div>
				</section>
							<section class="main-section" id="starting-benzodiazepines" tabindex="-1">
					<div class="head">
						<div class="container">
							<h2 class="main-heading">
								Starting Benzodiazepines								
							</h2>
							<div class="icon">
								<svg width="22" height="22" viewBox="0 0 22 22" fill="none" xmlns="http:/ /www.w3.org/2000/svg">
									<path fill-rule="evenodd" clip-rule="evenodd" d="M16 12H6V10H16V12Z" class="horizontal-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M10 16V6H12V16H10Z" class="vertical-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M11 20C15.9706 20 20 15.9706 20 11C20 6.02944 15.9706 2 11 2C6.02944 2 2 6.02944 2 11C2 15.9706 6.02944 20 11 20ZM11 22C17.0751 22 22 17.0751 22 11C22 4.92487 17.0751 0 11 0C4.92487 0 0 4.92487 0 11C0 17.0751 4.92487 22 11 22Z" class="outline" />
								</svg>
							</div>
						</div>
					</div>
					<div class="body">
						<div class="container">
							<article class="block--background  core-block" data-block-name="cep/background"><div class="container">
<div class="wp-block-cep-background is-style-red-background"><article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h3 class="wp-block-heading"><strong>Important information to collect before starting benzodiazepines</strong></h3>
</div></article>

<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h6 class="wp-block-heading"><strong>All prescribed and over-the-counter medications that the patient is currently taking</strong></h6>
</div></article>

<article class="block--list  core-block" data-block-name="core/list"><div class="container">
<ul class="wp-block-list">
<li>Including supplements, vitamins, and naturopathic treatments</li>
</ul>
</div></article>

<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h6 class="wp-block-heading"><strong>History of previous non-pharmacological and pharmacological alternatives tried</strong></h6>
</div></article>

<article class="block--list  core-block" data-block-name="core/list"><div class="container">
<ul class="wp-block-list">
<li>Understand what the patient means by &#8220;tried&#8221; and consider if the duration &#8220;tried&#8221; is long enough to evaluate efficacy/side effects</li>



<li>An adequate trial of non-pharmacological and pharmacological alternatives is approximately 6-8 weeks</li>
</ul>
</div></article>

<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h6 class="wp-block-heading"><strong>Substance use history</strong></h6>
</div></article>

<article class="block--list  core-block" data-block-name="core/list"><div class="container">
<ul class="wp-block-list">
<li>E.g. alcohol, cannabinoids, caffeine, nicotine</li>
</ul>
</div></article>

<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h6 class="wp-block-heading"><strong>History of adverse events</strong></h6>
</div></article>

<article class="block--list  core-block" data-block-name="core/list"><div class="container">
<ul class="wp-block-list">
<li>E.g. delirium, dementia or cognitive impairment, falls, fractures or motor-vehicle accidents</li>
</ul>
</div></article>

<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h6 class="wp-block-heading"><strong>Baseline assessment of anxiety disorders, insomnia or panic disorder</strong></h6>
</div></article>

<article class="block--list  core-block" data-block-name="core/list"><div class="container">
<ul class="wp-block-list">
<li>Use validated assessment tools such as, <a href="https://link.cep.health/benzohtml3" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">GAD-7 and PHQ</a> (PHQ section 4 on panic disorder) <sup>15</sup>, and the <a href="https://link.cep.health/benzohtml4" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">Insomnia Severity Index.</a><sup>16</sup></li>
</ul>
</div></article></div>
</div></article>

<article class="block--modal ">

<div class="outer">
  <div class="container">
    <div class="inner has-text-centered">
              <img decoding="async" src="https://tools.cep.health/wp-content/uploads/2020/05/info-icon.svg" alt="" />
                    <h6>Tips for safe benzodiazepine prescribing</h6>
                          <a data-modal="IXORXD" class="button open-modal" href="#" data-id="IXORXD">Click to view</a>
          </div>
  </div>
</div>

  <div data-modal="IXORXD" class="modal">
    <div class="inner text">
      <div class="close-wrapper">
                <a href="" class="close" data-wpel-link="internal">Close</a>
      </div>
      <div class="container">
                <div class="content">
          
                          <h4>Tips for safe benzodiazepine prescribing</h4>
                                      <ul>
<li>&#8220;Start low, go slow&#8221;</li>
<li>Prescribe the lowest dose necessary to control patient&#8217;s symptoms<sup>12,14,29</sup></li>
<li>Avoid starting long-acting benzodiazepines. Limit prescription to 2-4 weeks<sup>29</sup></li>
<li>Assess efficacy early and review regularly<sup>29</sup></li>
<li>Avoid prescribing benzodiazepines in older adults with a history of delirium, dementia, cognitive impairment, falls, fractures or motor-vehicle accidents<sup>28</sup></li>
</ul>
            
                  </div>
      </div>
    </div>
    <div class="overlay"></div>
</div></article>

<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h3 class="wp-block-heading">Safeguards for benzodiazepine prescribing</h3>
</div></article>

<article class="block--text-with-icon ">  <div class="container">
    
        <div class="columns is-flex is-gapless">
          <div class="column is-2-mobile is-1">
            <div class="inner">
              <img decoding="async" src="https://tools.cep.health/wp-content/uploads/2019/10/Checkmark-Large-2.svg" />
            </div>
          </div>
          <div class="column is-10-mobile is-11">
            <p>Avoid prescribing any combination of ≥3 central nervous system-active drugs (i.e. antidepressants, antipsychotics, antiepileptics, nonbenzodiazepine benzodiazepine receptor agonist hypnotics, opioids).<sup>28</sup></p>
          </div>
        </div>

    
        <div class="columns is-flex is-gapless">
          <div class="column is-2-mobile is-1">
            <div class="inner">
              <img decoding="async" src="https://tools.cep.health/wp-content/uploads/2019/10/Checkmark-Large-2.svg" />
            </div>
          </div>
          <div class="column is-10-mobile is-11">
            <p>Use limited dispensing<sup>9 </sup>and intermittent therapy, if appropriate (e.g. limit to 3 nights/week).<sup>14</sup></p>
          </div>
        </div>

    
        <div class="columns is-flex is-gapless">
          <div class="column is-2-mobile is-1">
            <div class="inner">
              <img decoding="async" src="https://tools.cep.health/wp-content/uploads/2019/10/Checkmark-Large-2.svg" />
            </div>
          </div>
          <div class="column is-10-mobile is-11">
            <p>Collaborate with the patient&#8217;s pharmacist regarding packaging options for older adults (e.g. dosette or blister pack), pill counts, home visits as well as patient education on safe storage and proper disposal.</p>
          </div>
        </div>

    
        <div class="columns is-flex is-gapless">
          <div class="column is-2-mobile is-1">
            <div class="inner">
              <img decoding="async" src="https://tools.cep.health/wp-content/uploads/2019/10/Checkmark-Large-2.svg" />
            </div>
          </div>
          <div class="column is-10-mobile is-11">
            <p>Set expectations and confirm an exit strategy with the patient. Implement treatment agreements &#8211; a sample benzodiazepine treatment agreement is available from the <a href="https://link.cep.health/benzohtml41" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">College of Physicians and Surgeons of Alberta</a>. Educate the patient about side effects and risk of overdose. Educate the patient about avoiding use with alcohol and over-the-counter sedatives (e.g. acetaminophen, codeine).</p>
          </div>
        </div>

    
        <div class="columns is-flex is-gapless">
          <div class="column is-2-mobile is-1">
            <div class="inner">
              <img decoding="async" src="https://tools.cep.health/wp-content/uploads/2019/10/Checkmark-Large-2.svg" />
            </div>
          </div>
          <div class="column is-10-mobile is-11">
            <p>Implement adjunctive non-pharmacological therapy (see Alternatives to benzodiazepines <a href="https://tools.cep.health/tool/managing-benzodiazepine-use-in-older-adults/#alternatives-to-benzodiazepines-for-anxiety" data-wpel-link="internal">for anxiety</a>, <a href="https://tools.cep.health/tool/managing-benzodiazepine-use-in-older-adults/#alternatives-to-benzodiazepines-for-insomnia" data-wpel-link="internal">insomnia</a>, or <a href="https://tools.cep.health/tool/managing-benzodiazepine-use-in-older-adults/#alternatives-to-benzodiazepines-for-panic-disorders" data-wpel-link="internal">panic disorder</a>).</p>
          </div>
        </div>

    
        <div class="columns is-flex is-gapless">
          <div class="column is-2-mobile is-1">
            <div class="inner">
              <img decoding="async" src="https://tools.cep.health/wp-content/uploads/2019/10/Checkmark-Large-2.svg" />
            </div>
          </div>
          <div class="column is-10-mobile is-11">
            <p>Monitor the patient closely for adverse events, such as cognitive impairment, delirium, falls, fractures and motor vehicle accidents.<sup>28 </sup>Be alert to the development of dependence &#8211; tolerance to the effects of benzodiazepines can develop quickly after only 3-6 weeks (i.e. within weeks) and then more of the drug is needed to achieve the same effect.<sup>12 </sup>Consider use of urine drug screening if misuse is suspected (note: urine drug screening does not detect all benzodiazepines).</p>
          </div>
        </div>

      </div>
</article>

<article class="block--background  core-block" data-block-name="cep/background"><div class="container">
<div class="wp-block-cep-background is-style-red-background"><article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h6 class="wp-block-heading">Increased risk: Benzodiazepines and opioids</h6>
</div></article>

<article class="block--paragraph  core-block" data-block-name="core/paragraph"><div class="container">
<p>The concurrent use of benzodiazepines and opioids is associated with an increased risk of adverse reactions due to the depression of the central nervous system exerted by both types of drugs:</p>
</div></article>

<article class="block--list  core-block" data-block-name="core/list"><div class="container">
<ul class="wp-block-list">
<li>Increases the risk of cognitive effects, falls, motor vehicle accidents, overdoses and drug-related death <sup>27, 28, 32</sup></li>



<li>Risks are increased further when benzodiazepines are taken concurrently with alcohol</li>



<li>The expert perspective is that opioids and benzodiazepines should rarely be prescribed together<sup> 32</sup></li>



<li>For patients who may benefit from both an opioid taper and a benzodiazepine taper, consider completing the opioid taper first or taper the medication that the patient is most willing to taper first<sup> 9</sup></li>
</ul>
</div></article></div>
</div></article>

<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h3 class="wp-block-heading" id="benzosON">Benzodiazepine available in Ontario<sup>7, 21, 30, 31</sup></h3>
</div></article>

<article class="block--drug-options ">
<div class="container">
  <h5><span style="font-size: 13.5px;">Scroll (left-right) for details</h5>
          <div class="slider">
        <div class="inner-stage">
          <ul>
            
                <li>
                  <div class="inner">
                    <span class="subhead">Long-acting</span>
                    <h6>Chlordiazepoxide</h6>
                    <div class="page" title="Page 5">
<div class="section">
<div class="layoutArea">
<div class="column">
<p><strong>Covered by Ontario Drug Benefit<sup>30</sup></strong></p>
<p><strong><span style="font-size: 1.5rem;">Formulations</span></strong></p>
<ul>
<li>Capsule: 5 mg, 10 mg, 25 mg</li>
</ul>
</div>
</div>
<div class="layoutArea">
<div class="column">
<p><strong>Approximate equivalent to 5mg diazepam oral dose</strong></p>
<ul>
<li>10 mg</li>
</ul>
</div>
</div>
<div class="layoutArea">
<div class="column">
<p><strong>Half-life (hours)**</strong></p>
<ul>
<li>100</li>
</ul>
</div>
</div>
</div>
</div>
                                      </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead">Long-acting</span>
                    <h6>Clorazepate</h6>
                    <div class="layoutArea">
<div class="column">
<div class="layoutArea">
<div class="column">
<p><strong>Covered by Ontario Drug Benefit<sup>30</sup></strong></p>
<p><strong><span style="font-size: 1.5rem;">Formulations</span></strong></p>
<ul>
<li>Capsule: 3.75 mg, 7.5 mg, 15 mg</li>
</ul>
</div>
</div>
<div class="layoutArea">
<div class="column">
<p><strong>Approximate equivalent to 5mg diazepam oral dose</strong></p>
<ul>
<li>7.5 mg</li>
</ul>
</div>
</div>
<div class="layoutArea">
<div class="column">
<p><strong>Half-life (hours)**</strong></p>
<ul>
<li>100</li>
</ul>
</div>
</div>
</div>
</div>
                                      </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead">Long-acting</span>
                    <h6>Diazepam</h6>
                    <div class="layoutArea">
<div class="column">
<p><strong>Covered by Ontario Drug Benefit<sup>30</sup></strong></p>
<p><strong><span style="font-size: 1.5rem;">Formulations</span></strong></p>
<ul>
<li>Tablet: 2 mg^, 5 mg^, 10 mg^</li>
</ul>
</div>
</div>
<div class="layoutArea">
<div class="column">
<p><strong>Approximate equivalent to 5mg diazepam oral dose</strong></p>
<ul>
<li>5 mg</li>
</ul>
</div>
</div>
<div class="layoutArea">
<div class="column">
<p><strong>Half-life (hours)**</strong></p>
<ul>
<li>100</li>
</ul>
</div>
</div>
                                      </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead">Long-acting</span>
                    <h6>Flurazepam</h6>
                    <div class="layoutArea">
<div class="column">
<p><strong>Covered by Ontario Drug Benefit<sup>30</sup></strong></p>
<p><strong><span style="font-size: 1.5rem;">Formulations</span></strong></p>
<ul>
<li><span style="font-size: 1.5rem;">Capsule: 15 mg, 30 mg</span></li>
</ul>
</div>
</div>
<div class="layoutArea">
<div class="column">
<p><strong>Approximate equivalent to 5mg diazepam oral dose</strong></p>
<ul>
<li>15 mg</li>
</ul>
</div>
</div>
<div class="layoutArea">
<div class="column">
<p><strong>Half-life (hours)**</strong></p>
<ul>
<li>100</li>
</ul>
</div>
</div>
                                      </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead">Intermediate-acting</span>
                    <h6>Alprazolam</h6>
                    <div class="layoutArea">
<div class="column">
<p><strong>Only 0.25 mg, 0.5 mg covered by Ontario Drug Benefit<sup>30</sup></strong></p>
<p><strong><span style="font-size: 1.5rem;">Formulations</span></strong></p>
<ul>
<li>Tablet: 0.25 mg^, 0.5 mg^, 1 mg^, 2 mg</li>
</ul>
</div>
</div>
<div class="layoutArea">
<div class="column">
<p><strong>Approximate equivalent to 5mg diazepam oral dose</strong></p>
<ul>
<li>0.5 mg</li>
</ul>
</div>
</div>
<div class="layoutArea">
<div class="column">
<p><strong>Half-life (hours)**</strong></p>
<ul>
<li>12-15</li>
</ul>
</div>
</div>
                                      </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead">Intermediate-acting</span>
                    <h6>Bromazepam</h6>
                    <div class="layoutArea">
<div class="column">
<p><strong>Covered by Ontario Drug Benefit<sup>30</sup></strong></p>
<p><strong><span style="font-size: 1.5rem;">Formulations</span></strong></p>
<ul>
<li>Tablet: 1.5 mg^, 3mg^, 6 mg^</li>
</ul>
</div>
</div>
<div class="layoutArea">
<div class="column">
<p><strong>Approximate equivalent to 5mg diazepam oral dose</strong></p>
<ul>
<li>3 mg</li>
</ul>
</div>
</div>
<div class="layoutArea">
<div class="column">
<p><strong>Half-life (hours)**</strong></p>
<ul>
<li>8-30</li>
</ul>
</div>
</div>
                                      </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead">Intermediate-acting</span>
                    <h6>Clobazam</h6>
                    <div class="layoutArea">
<div class="column">
<p><strong>Covered by Ontario Drug Benefit<sup>30</sup></strong></p>
<p><strong><span style="font-size: 1.5rem;">Formulations</span></strong></p>
<ul>
<li>Tablet: 10 mg^</li>
</ul>
</div>
</div>
<div class="layoutArea">
<div class="column">
<p><strong>Approximate equivalent to 5mg diazepam oral dose</strong></p>
<ul>
<li>10 mg</li>
</ul>
</div>
</div>
<div class="layoutArea">
<div class="column">
<p><strong>Half-life (hours)**</strong></p>
<ul>
<li>10-46</li>
</ul>
</div>
</div>
                                      </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead">Intermediate-acting</span>
                    <h6>Clonzepam</h6>
                    <div class="layoutArea">
<div class="column">
<p><strong>Only 0.5 mg^, 2 mg^ covered by Ontario Drug Benefit</strong></p>
<p><strong><span style="font-size: 1.5rem;">Formulations</span></strong></p>
<ul>
<li>Tablet: 0.25 mg, 0.5 mg^, 1 mg, 2 mg^</li>
</ul>
</div>
</div>
<div class="layoutArea">
<div class="column">
<p><strong>Approximate equivalent to 5mg diazepam oral dose</strong></p>
<ul>
<li>0.25 mg</li>
</ul>
</div>
</div>
<div class="layoutArea">
<div class="column">
<p><strong>Half-life (hours)**</strong></p>
<ul>
<li>20-80</li>
</ul>
</div>
</div>
                                      </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead">Intermediate-acting</span>
                    <h6>Lorazapem</h6>
                    <div class="layoutArea">
<div class="column">
<p><strong>Covered by Ontario Drug Benefit<sup>30</sup></strong></p>
<p><strong><span style="font-size: 1.5rem;">Formulations</span></strong></p>
<ul>
<li>Tablet: 0.5 mg, 1 mg^, 2 mg^</li>
</ul>
</div>
</div>
<div class="layoutArea">
<div class="column">
<p><strong>Approximate equivalent to 5mg diazepam oral dose</strong></p>
<ul>
<li>1 mg</li>
</ul>
</div>
</div>
<div class="layoutArea">
<div class="column">
<p><strong>Half-life (hours)**</strong></p>
<ul>
<li>10-20</li>
</ul>
</div>
</div>
                                      </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead">Intermediate-acting</span>
                    <h6>Nitrazapem</h6>
                    <div class="layoutArea">
<div class="column">
<p><strong>Covered by Ontario Drug Benefit<sup>30</sup></strong></p>
<p><strong><span style="font-size: 1.5rem;">Formulations</span></strong></p>
<ul>
<li>Tablet: 5 mg^, 10 mg^</li>
</ul>
</div>
</div>
<div class="layoutArea">
<div class="column">
<p><strong>Approximate equivalent to 5mg diazepam oral dose</strong></p>
<ul>
<li>5 mg</li>
</ul>
</div>
</div>
<div class="layoutArea">
<div class="column">
<p><strong>Half-life (hours)**</strong></p>
<ul>
<li>16-55</li>
</ul>
</div>
</div>
                                      </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead">Intermediate-acting</span>
                    <h6>Oxazapem</h6>
                    <div class="layoutArea">
<div class="column">
<p><strong>Covered by Ontario Drug Benefit<sup>30</sup></strong></p>
<p><strong><span style="font-size: 1.5rem;">Formulations</span></strong></p>
<ul>
<li>Tablet: 10 mg^, 15 mg^, 30 mg^</li>
</ul>
</div>
</div>
<div class="layoutArea">
<div class="column">
<p><strong>Approximate equivalent to 5mg diazepam oral dose</strong></p>
<ul>
<li>15 mg</li>
</ul>
</div>
</div>
<div class="layoutArea">
<div class="column">
<p><strong>Half-life (hours)**</strong></p>
<ul>
<li>5-15</li>
</ul>
</div>
</div>
                                      </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead">Intermediate-acting</span>
                    <h6>Temazapem</h6>
                    <div class="layoutArea">
<div class="column">
<p><strong>Covered by Ontario Drug Benefit<sup>30</sup></strong></p>
<p><strong><span style="font-size: 1.5rem;">Formulations</span></strong></p>
<ul>
<li>Capsule: 15 mg, 30 mg</li>
</ul>
</div>
</div>
<div class="layoutArea">
<div class="column">
<p><strong>Approximate equivalent to 5mg diazepam oral dose</strong></p>
<ul>
<li>15 mg</li>
</ul>
</div>
</div>
<div class="layoutArea">
<div class="column">
<p><strong>Half-life (hours)**</strong></p>
<ul>
<li>10-20</li>
</ul>
</div>
</div>
                                      </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead">Short-acting</span>
                    <h6>Triazolam</h6>
                    <div class="layoutArea">
<div class="column">
<p><strong>Covered by Ontario Drug Benefit<sup>30</sup></strong></p>
<p><strong><span style="font-size: 1.5rem;">Formulations</span></strong></p>
<ul>
<li>Tablet: 0.125 mg^, 0.25 mg^</li>
</ul>
</div>
</div>
<div class="layoutArea">
<div class="column">
<p><strong>Approximate equivalent to 5mg diazepam oral dose</strong></p>
<ul>
<li>0.25 mg</li>
</ul>
</div>
</div>
<div class="layoutArea">
<div class="column">
<p><strong>Half-life (hours)**</strong></p>
<ul>
<li>1.5-5</li>
</ul>
</div>
</div>
                                      </div>
                                  </li>

                      </ul>
        </div>
      </div>
    </div>
</article>

<article class="block--paragraph  core-block" data-block-name="core/paragraph"><div class="container">
<p style="font-size:12px">^ Scored <br>** Parent compound and active metabolite</p>
</div></article>						</div>
					</div>
				</section>
							<section class="main-section" id="continuing-benzodiazepines" tabindex="-1">
					<div class="head">
						<div class="container">
							<h2 class="main-heading">
								Continuing Benzodiazepines								
							</h2>
							<div class="icon">
								<svg width="22" height="22" viewBox="0 0 22 22" fill="none" xmlns="http:/ /www.w3.org/2000/svg">
									<path fill-rule="evenodd" clip-rule="evenodd" d="M16 12H6V10H16V12Z" class="horizontal-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M10 16V6H12V16H10Z" class="vertical-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M11 20C15.9706 20 20 15.9706 20 11C20 6.02944 15.9706 2 11 2C6.02944 2 2 6.02944 2 11C2 15.9706 6.02944 20 11 20ZM11 22C17.0751 22 22 17.0751 22 11C22 4.92487 17.0751 0 11 0C4.92487 0 0 4.92487 0 11C0 17.0751 4.92487 22 11 22Z" class="outline" />
								</svg>
							</div>
						</div>
					</div>
					<div class="body">
						<div class="container">
							<article class="block--paragraph  core-block" data-block-name="core/paragraph"><div class="container">
<p>For patients continuing on a benzodiazepine, ensure safeguards are put in place to reduce harms and revisit the <a href="#discontinuing-benzodiazepines">tapering conversation</a> if/when appropriate.</p>
</div></article>

<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h3 class="wp-block-heading" id="safeguards">Safeguards for benzodiazepine prescribing</h3>
</div></article>

<article class="block--text-with-icon ">  <div class="container">
    
        <div class="columns is-flex is-gapless">
          <div class="column is-2-mobile is-1">
            <div class="inner">
              <img decoding="async" src="https://tools.cep.health/wp-content/uploads/2019/10/Checkmark-Large-2.svg" />
            </div>
          </div>
          <div class="column is-10-mobile is-11">
            <p>Avoid prescribing any combination of ≥3 central nervous system-active drugs (i.e. antidepressants, antipsychotics, antiepileptics, nonbenzodiazepine benzodiazepine receptor agonist hypnotics, opioids).<sup>28</sup></p>
          </div>
        </div>

    
        <div class="columns is-flex is-gapless">
          <div class="column is-2-mobile is-1">
            <div class="inner">
              <img decoding="async" src="https://tools.cep.health/wp-content/uploads/2019/10/Checkmark-Large-2.svg" />
            </div>
          </div>
          <div class="column is-10-mobile is-11">
            <p>Use limited dispensing<sup>9 </sup>and intermittent therapy, if appropriate (e.g. limit to 3 nights/week).<sup>14</sup></p>
          </div>
        </div>

    
        <div class="columns is-flex is-gapless">
          <div class="column is-2-mobile is-1">
            <div class="inner">
              <img decoding="async" src="https://tools.cep.health/wp-content/uploads/2019/10/Checkmark-Large-2.svg" />
            </div>
          </div>
          <div class="column is-10-mobile is-11">
            <p>Collaborate with the patient&#8217;s pharmacist regarding packaging options for older adults (e.g. dosette or blister pack), pill counts, home visits as well as patient education on safe storage and proper disposal.</p>
          </div>
        </div>

    
        <div class="columns is-flex is-gapless">
          <div class="column is-2-mobile is-1">
            <div class="inner">
              <img decoding="async" src="https://tools.cep.health/wp-content/uploads/2019/10/Checkmark-Large-2.svg" />
            </div>
          </div>
          <div class="column is-10-mobile is-11">
            <p>Set expectations and confirm an exit strategy with the patient. Implement treatment agreements &#8211; a sample benzodiazepine treatment agreement is available from the <a href="https://link.cep.health/benzohtml41" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">College of Physicians and Surgeons of Alberta</a>. Educate the patient about side effects and risk of overdose. Educate the patient about avoiding use with alcohol and over-the-counter sedatives (e.g. acetaminophen, codeine).</p>
          </div>
        </div>

    
        <div class="columns is-flex is-gapless">
          <div class="column is-2-mobile is-1">
            <div class="inner">
              <img decoding="async" src="https://tools.cep.health/wp-content/uploads/2019/10/Checkmark-Large-2.svg" />
            </div>
          </div>
          <div class="column is-10-mobile is-11">
            <p>Implement adjunctive non-pharmacological therapy (see Alternatives to benzodiazepines for<a href="https://tools.cep.health/tool/managing-benzodiazepine-use-in-older-adults/#alternatives-to-benzodiazepines-for-anxiety" data-wpel-link="internal"> anxiety,</a> <a href="https://tools.cep.health/tool/managing-benzodiazepine-use-in-older-adults/#alternatives-to-benzodiazepines-for-insomnia" data-wpel-link="internal">insomnia,</a> or <a href="https://tools.cep.health/tool/managing-benzodiazepine-use-in-older-adults/#alternatives-to-benzodiazepines-for-panic-disorders" data-wpel-link="internal">panic disorders</a>).</p>
          </div>
        </div>

    
        <div class="columns is-flex is-gapless">
          <div class="column is-2-mobile is-1">
            <div class="inner">
              <img decoding="async" src="https://tools.cep.health/wp-content/uploads/2019/10/Checkmark-Large-2.svg" />
            </div>
          </div>
          <div class="column is-10-mobile is-11">
            <p>Monitor the patient closely for adverse events, such as cognitive impairment, delirium, falls, fractures and motor vehicle accidents.<sup>28 </sup>Be alert to the development of dependence &#8211; tolerance to the effects of benzodiazepines can develop quickly after only 3-6 weeks (i.e. within weeks) and then more of the drug is needed to achieve the same effect.<sup>12 </sup>Consider use of urine drug screening if misuse is suspected (note: urine drug screening does not detect all benzodiazepines).</p>
          </div>
        </div>

      </div>
</article>

<article class="block--background  core-block" data-block-name="cep/background"><div class="container">
<div class="wp-block-cep-background is-style-red-background"><article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h6 class="wp-block-heading">Increased risk: Benzodiazepines and opioids</h6>
</div></article>

<article class="block--paragraph  core-block" data-block-name="core/paragraph"><div class="container">
<p>The concurrent use of benzodiazepines and opioids is associated with an increased risk of adverse reactions due to the depression of the central nervous system exerted by both types of drugs:</p>
</div></article>

<article class="block--list  core-block" data-block-name="core/list"><div class="container">
<ul class="wp-block-list">
<li>Increases the risk of cognitive effects, falls, motor vehicle accidents, overdoses and drug-related death <sup>27, 28, 32</sup></li>



<li>Risks are increased further when benzodiazepines are taken concurrently with alcohol</li>



<li>The expert perspective is that opioids and benzodiazepines should rarely be prescribed together<sup> 32</sup></li>



<li>For patients who may benefit from both an opioid taper and a benzodiazepine taper, consider completing the opioid taper first or taper the medication that the patient is most willing to taper first<sup> 9</sup></li>
</ul>
</div></article></div>
</div></article>

<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h3 class="wp-block-heading">Benzodiazepine available in Ontario<sup>7, 21, 30, 31</sup></h3>
</div></article>

<article class="block--drug-options ">
<div class="container">
  <h5><span style="font-size: 13.5px;">Scroll (left-right) for details</h5>
          <div class="slider">
        <div class="inner-stage">
          <ul>
            
                <li>
                  <div class="inner">
                    <span class="subhead">Long-acting</span>
                    <h6>Chlordiazepoxide</h6>
                    <div class="page" title="Page 5">
<div class="section">
<div class="layoutArea">
<div class="column">
<p><strong>Covered by Ontario Drug Benefit<sup>30</sup></strong></p>
<p><strong><span style="font-size: 1.5rem;">Formulations</span></strong></p>
<ul>
<li>Capsule: 5 mg, 10 mg, 25 mg</li>
</ul>
</div>
</div>
<div class="layoutArea">
<div class="column">
<p><strong>Approximate equivalent to 5mg diazepam oral dose</strong></p>
<ul>
<li>10 mg</li>
</ul>
</div>
</div>
<div class="layoutArea">
<div class="column">
<p><strong>Half-life (hours)**</strong></p>
<ul>
<li>100</li>
</ul>
</div>
</div>
</div>
</div>
                                      </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead">Long-acting</span>
                    <h6>Clorazepate</h6>
                    <div class="layoutArea">
<div class="column">
<div class="layoutArea">
<div class="column">
<p><strong>Covered by Ontario Drug Benefit<sup>30</sup></strong></p>
<p><strong><span style="font-size: 1.5rem;">Formulations</span></strong></p>
<ul>
<li>Capsule: 3.75 mg, 7.5 mg, 15 mg</li>
</ul>
</div>
</div>
<div class="layoutArea">
<div class="column">
<p><strong>Approximate equivalent to 5mg diazepam oral dose</strong></p>
<ul>
<li>7.5 mg</li>
</ul>
</div>
</div>
<div class="layoutArea">
<div class="column">
<p><strong>Half-life (hours)**</strong></p>
<ul>
<li>100</li>
</ul>
</div>
</div>
</div>
</div>
                                      </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead">Long-acting</span>
                    <h6>Diazepam</h6>
                    <div class="layoutArea">
<div class="column">
<p><strong>Covered by Ontario Drug Benefit<sup>30</sup></strong></p>
<p><strong><span style="font-size: 1.5rem;">Formulations</span></strong></p>
<ul>
<li>Tablet: 2 mg^, 5 mg^, 10 mg^</li>
</ul>
</div>
</div>
<div class="layoutArea">
<div class="column">
<p><strong>Approximate equivalent to 5mg diazepam oral dose</strong></p>
<ul>
<li>5 mg</li>
</ul>
</div>
</div>
<div class="layoutArea">
<div class="column">
<p><strong>Half-life (hours)**</strong></p>
<ul>
<li>100</li>
</ul>
</div>
</div>
                                      </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead">Long-acting</span>
                    <h6>Flurazepam</h6>
                    <div class="layoutArea">
<div class="column">
<p><strong>Covered by Ontario Drug Benefit<sup>30</sup></strong></p>
<p><strong><span style="font-size: 1.5rem;">Formulations</span></strong></p>
<ul>
<li><span style="font-size: 1.5rem;">Capsule: 15 mg, 30 mg</span></li>
</ul>
</div>
</div>
<div class="layoutArea">
<div class="column">
<p><strong>Approximate equivalent to 5mg diazepam oral dose</strong></p>
<ul>
<li>15 mg</li>
</ul>
</div>
</div>
<div class="layoutArea">
<div class="column">
<p><strong>Half-life (hours)**</strong></p>
<ul>
<li>100</li>
</ul>
</div>
</div>
                                      </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead">Intermediate-acting</span>
                    <h6>Alprazolam</h6>
                    <div class="layoutArea">
<div class="column">
<p><strong>Only 0.25 mg, 0.5 mg covered by Ontario Drug Benefit<sup>30</sup></strong></p>
<p><strong><span style="font-size: 1.5rem;">Formulations</span></strong></p>
<ul>
<li>Tablet: 0.25 mg^, 0.5 mg^, 1 mg^, 2 mg</li>
</ul>
</div>
</div>
<div class="layoutArea">
<div class="column">
<p><strong>Approximate equivalent to 5mg diazepam oral dose</strong></p>
<ul>
<li>0.5 mg</li>
</ul>
</div>
</div>
<div class="layoutArea">
<div class="column">
<p><strong>Half-life (hours)**</strong></p>
<ul>
<li>12-15</li>
</ul>
</div>
</div>
                                      </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead">Intermediate-acting</span>
                    <h6>Bromazepam</h6>
                    <div class="layoutArea">
<div class="column">
<p><strong>Covered by Ontario Drug Benefit<sup>30</sup></strong></p>
<p><strong><span style="font-size: 1.5rem;">Formulations</span></strong></p>
<ul>
<li>Tablet: 1.5 mg^, 3mg^, 6 mg^</li>
</ul>
</div>
</div>
<div class="layoutArea">
<div class="column">
<p><strong>Approximate equivalent to 5mg diazepam oral dose</strong></p>
<ul>
<li>3 mg</li>
</ul>
</div>
</div>
<div class="layoutArea">
<div class="column">
<p><strong>Half-life (hours)**</strong></p>
<ul>
<li>8-30</li>
</ul>
</div>
</div>
                                      </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead">Intermediate-acting</span>
                    <h6>Clobazam</h6>
                    <div class="layoutArea">
<div class="column">
<p><strong>Covered by Ontario Drug Benefit<sup>30</sup></strong></p>
<p><strong><span style="font-size: 1.5rem;">Formulations</span></strong></p>
<ul>
<li>Tablet: 10 mg^</li>
</ul>
</div>
</div>
<div class="layoutArea">
<div class="column">
<p><strong>Approximate equivalent to 5mg diazepam oral dose</strong></p>
<ul>
<li>10 mg</li>
</ul>
</div>
</div>
<div class="layoutArea">
<div class="column">
<p><strong>Half-life (hours)**</strong></p>
<ul>
<li>10-46</li>
</ul>
</div>
</div>
                                      </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead">Intermediate-acting</span>
                    <h6>Clonzepam</h6>
                    <div class="layoutArea">
<div class="column">
<p><strong>Only 0.5 mg^, 2 mg^ covered by Ontario Drug Benefit</strong></p>
<p><strong><span style="font-size: 1.5rem;">Formulations</span></strong></p>
<ul>
<li>Tablet: 0.25 mg, 0.5 mg^, 1 mg, 2 mg^</li>
</ul>
</div>
</div>
<div class="layoutArea">
<div class="column">
<p><strong>Approximate equivalent to 5mg diazepam oral dose</strong></p>
<ul>
<li>0.25 mg</li>
</ul>
</div>
</div>
<div class="layoutArea">
<div class="column">
<p><strong>Half-life (hours)**</strong></p>
<ul>
<li>20-80</li>
</ul>
</div>
</div>
                                      </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead">Intermediate-acting</span>
                    <h6>Lorazapem</h6>
                    <div class="layoutArea">
<div class="column">
<p><strong>Covered by Ontario Drug Benefit<sup>30</sup></strong></p>
<p><strong><span style="font-size: 1.5rem;">Formulations</span></strong></p>
<ul>
<li>Tablet: 0.5 mg, 1 mg^, 2 mg^</li>
</ul>
</div>
</div>
<div class="layoutArea">
<div class="column">
<p><strong>Approximate equivalent to 5mg diazepam oral dose</strong></p>
<ul>
<li>1 mg</li>
</ul>
</div>
</div>
<div class="layoutArea">
<div class="column">
<p><strong>Half-life (hours)**</strong></p>
<ul>
<li>10-20</li>
</ul>
</div>
</div>
                                      </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead">Intermediate-acting</span>
                    <h6>Nitrazapem</h6>
                    <div class="layoutArea">
<div class="column">
<p><strong>Covered by Ontario Drug Benefit<sup>30</sup></strong></p>
<p><strong><span style="font-size: 1.5rem;">Formulations</span></strong></p>
<ul>
<li>Tablet: 5 mg^, 10 mg^</li>
</ul>
</div>
</div>
<div class="layoutArea">
<div class="column">
<p><strong>Approximate equivalent to 5mg diazepam oral dose</strong></p>
<ul>
<li>5 mg</li>
</ul>
</div>
</div>
<div class="layoutArea">
<div class="column">
<p><strong>Half-life (hours)**</strong></p>
<ul>
<li>16-55</li>
</ul>
</div>
</div>
                                      </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead">Intermediate-acting</span>
                    <h6>Oxazapem</h6>
                    <div class="layoutArea">
<div class="column">
<p><strong>Covered by Ontario Drug Benefit<sup>30</sup></strong></p>
<p><strong><span style="font-size: 1.5rem;">Formulations</span></strong></p>
<ul>
<li>Tablet: 10 mg^, 15 mg^, 30 mg^</li>
</ul>
</div>
</div>
<div class="layoutArea">
<div class="column">
<p><strong>Approximate equivalent to 5mg diazepam oral dose</strong></p>
<ul>
<li>15 mg</li>
</ul>
</div>
</div>
<div class="layoutArea">
<div class="column">
<p><strong>Half-life (hours)**</strong></p>
<ul>
<li>5-15</li>
</ul>
</div>
</div>
                                      </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead">Intermediate-acting</span>
                    <h6>Temazapem</h6>
                    <div class="layoutArea">
<div class="column">
<p><strong>Covered by Ontario Drug Benefit<sup>30</sup></strong></p>
<p><strong><span style="font-size: 1.5rem;">Formulations</span></strong></p>
<ul>
<li>Capsule: 15 mg, 30 mg</li>
</ul>
</div>
</div>
<div class="layoutArea">
<div class="column">
<p><strong>Approximate equivalent to 5mg diazepam oral dose</strong></p>
<ul>
<li>15 mg</li>
</ul>
</div>
</div>
<div class="layoutArea">
<div class="column">
<p><strong>Half-life (hours)**</strong></p>
<ul>
<li>10-20</li>
</ul>
</div>
</div>
                                      </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead">Short-acting</span>
                    <h6>Triazolam</h6>
                    <div class="layoutArea">
<div class="column">
<p><strong>Covered by Ontario Drug Benefit<sup>30</sup></strong></p>
<p><strong><span style="font-size: 1.5rem;">Formulations</span></strong></p>
<ul>
<li>Tablet: 0.125 mg^, 0.25 mg^</li>
</ul>
</div>
</div>
<div class="layoutArea">
<div class="column">
<p><strong>Approximate equivalent to 5mg diazepam oral dose</strong></p>
<ul>
<li>0.25 mg</li>
</ul>
</div>
</div>
<div class="layoutArea">
<div class="column">
<p><strong>Half-life (hours)**</strong></p>
<ul>
<li>1.5-5</li>
</ul>
</div>
</div>
                                      </div>
                                  </li>

                      </ul>
        </div>
      </div>
    </div>
</article>

<article class="block--paragraph  core-block" data-block-name="core/paragraph"><div class="container">
<p style="font-size:12px">^ Scored <br>** Parent compound and active metabolite</p>
</div></article>						</div>
					</div>
				</section>
							<section class="main-section" id="alternatives-to-benzodiazepines-for-anxiety" tabindex="-1">
					<div class="head">
						<div class="container">
							<h2 class="main-heading">
								Alternatives to Benzodiazepines for Anxiety								
							</h2>
							<div class="icon">
								<svg width="22" height="22" viewBox="0 0 22 22" fill="none" xmlns="http:/ /www.w3.org/2000/svg">
									<path fill-rule="evenodd" clip-rule="evenodd" d="M16 12H6V10H16V12Z" class="horizontal-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M10 16V6H12V16H10Z" class="vertical-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M11 20C15.9706 20 20 15.9706 20 11C20 6.02944 15.9706 2 11 2C6.02944 2 2 6.02944 2 11C2 15.9706 6.02944 20 11 20ZM11 22C17.0751 22 22 17.0751 22 11C22 4.92487 17.0751 0 11 0C4.92487 0 0 4.92487 0 11C0 17.0751 4.92487 22 11 22Z" class="outline" />
								</svg>
							</div>
						</div>
					</div>
					<div class="body">
						<div class="container">
							<article class="block--paragraph  core-block" data-block-name="core/paragraph"><div class="container">
<p class="is-style-default">The following outline many of the non-pharmacological and pharmacological alternative therapy options to benzodiazepines for older adults, along with the level of evidence and adverse effects associated with each therapy. </p>
</div></article>

<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h3 class="wp-block-heading">Non-pharmacological options<sup>1,2</sup></h3>
</div></article>

<article class="block--text-with-icon ">  <div class="container">
    
        <div class="columns is-flex is-gapless">
          <div class="column is-2-mobile is-1">
            <div class="inner">
              <img decoding="async" src="https://tools.cep.health/wp-content/uploads/2019/10/Checkmark-Large-2.svg" />
            </div>
          </div>
          <div class="column is-10-mobile is-11">
            <p>Non-pharmacological alternatives are the preferred treatment for anxiety disorders, insomnia or panic disorder among older adults.</p>
          </div>
        </div>

      </div>
</article>

<article class="block--drug-options ">
<div class="container">
  <h5><span style="font-size: 13.5px;">Scroll (left-right) for details</h5>
          <div class="slider">
        <div class="inner-stage">
          <ul>
            
                <li>
                  <div class="inner">
                    <span class="subhead"></span>
                    <h6>Cognitive behavioural therapy</h6>
                    <p><strong>Level of evidence • • •</strong></p>
<p>Efficacy of psychological treatment is similar to that of pharmacotherapy for the treatment of anxiety disorders in older patients</p>
                                      </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead"></span>
                    <h6>Progressive muscle relaxation</h6>
                    <p><strong>Level of evidence • • •</strong></p>
<p>Efficacy of psychological treatment is similar to that of pharmacotherapy for the treatment of anxiety disorders in older patients</p>
                                      </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead"></span>
                    <h6>Psychological therapy (supportive psychotherapy)</h6>
                    <p><strong>Level of evidence • •</strong></p>
<p>Efficacy of psychological treatment is similar to that of pharmacotherapy for the treatment of anxiety disorders in older patients</p>
                                      </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead"></span>
                    <h6>Physical activity</h6>
                    <p><strong>Level of evidence •</strong></p>
<p>Physical activity: 2.5 hours of moderate to higher intensity aerobic activity/week in bouts of 10minutes or more<sup>33</sup></p>
                                      </div>
                                  </li>

                      </ul>
        </div>
      </div>
    </div>
</article>

<article class="block--paragraph  core-block" data-block-name="core/paragraph"><div class="container">
<p><em>Level of evidence: </em><br><strong>· · · </strong><em>= meta-analysis or at least 2 randomized controlled trials that included a placebo condition, </em><br><strong>· · </strong><em>= at least 1 randomized controlled trial with placebo or active comparison condition,</em><br><strong>· </strong><em>= uncontrolled trial with at least 10 subjects</em></p>
</div></article>

<article class="block--text-with-icon ">  <div class="container">
    
        <div class="columns is-flex is-gapless">
          <div class="column is-2-mobile is-1">
            <div class="inner">
              <img decoding="async" src="https://tools.cep.health/wp-content/uploads/2019/10/Eye.svg" />
            </div>
          </div>
          <div class="column is-10-mobile is-11">
            <p>See <a href="#provider-and-patient-resources">Patient Resources</a> for more information.</p>
          </div>
        </div>

      </div>
</article>

<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h3 class="wp-block-heading">Pharmacological options</h3>
</div></article>

<article class="block--text-with-icon ">  <div class="container">
    
        <div class="columns is-flex is-gapless">
          <div class="column is-2-mobile is-1">
            <div class="inner">
              <img decoding="async" src="https://tools.cep.health/wp-content/uploads/2019/10/Yellow-Notice.svg" />
            </div>
          </div>
          <div class="column is-10-mobile is-11">
            <p>As patients age, their bodies respond to medications differently, making them more susceptible to adverse events and drug-drug interactions. If using pharmacological alternatives in older patients, consider patient factors and use the &#8220;<strong>start low, go slow</strong>&#8221; approach.</p>
          </div>
        </div>

      </div>
</article>

<article class="block--drug-options ">
<div class="container">
  <h5><span style="font-size: 13.5px;">Scroll (left-right) for details</h5>
          <div class="slider">
        <div class="inner-stage">
          <ul>
            
                <li>
                  <div class="inner">
                    <span class="subhead">First-line treatment (SSRIs)</span>
                    <h6>Escitalopram and Sertraline</h6>
                    <p><strong>Level of evidence • • •</strong></p>
<p><strong>Adverse effects</strong></p>
<ul>
<li>Insomnia</li>
<li>Somnolence</li>
<li>Sedation</li>
<li>Nausea</li>
<li>GI</li>
<li>Sexual Dysfunction</li>
<li>Qt prolongation</li>
<li>Dizziness</li>
<li>Dry mouth</li>
<li>Hyponatremia</li>
</ul>
<p><strong>Additional information</strong></p>
<ul>
<li>SSRI appears as a class in 2019 AGS Beers Criteria®*</li>
</ul>
                                      </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead">First-line treatment (SNRIs)</span>
                    <h6>Duloxetine and Venlafaxine ER</h6>
                    <div class="column">
<p><strong>Level of evidence • • •</strong></p>
<p><strong>Adverse effects</strong></p>
<ul>
<li>Insomnia</li>
<li>Sleep disturbances</li>
<li>Sedation</li>
<li>Nausea</li>
<li>GI</li>
<li>Decreased appetite</li>
<li>Increased BP</li>
<li>Dizziness</li>
<li>Hyponatremia</li>
</ul>
<p><strong>Additional information</strong></p>
<ul>
<li>SNRI appears as a class in 2019 AGS Beers Criteria®*</li>
</ul>
</div>
                                      </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead">First-line treatment</span>
                    <h6>Pregabalin</h6>
                    <div class="column">
<p><strong>Level of evidence • • •</strong></p>
<p><strong>Adverse effects</strong></p>
<ul>
<li>Sedation</li>
<li>Nausea</li>
<li>GI</li>
<li>Increased appetite and weight</li>
<li>Dizziness</li>
<li>Dry mouth</li>
</ul>
<p><strong>Additional information</strong></p>
<ul>
<li>Pregabalin has the most robust data in older patients that demonstrates significant improvements and good tolerability</li>
</ul>
</div>
                                      </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead">Second-line treatment</span>
                    <h6>Bupropion SR/XL</h6>
                    <div class="column">
<p><strong>Level of evidence • • </strong></p>
<p><strong>Adverse effects</strong></p>
<ul>
<li>Insomnia</li>
<li>GI</li>
<li>Decreased appetite</li>
<li>Increased seizure activity</li>
</ul>
</div>
                                      </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead">Third-line treatment (SSRIs)</span>
                    <h6>Citalopram</h6>
                    <div class="column">
<p><strong>Level of evidence •</strong></p>
<p><strong>Adverse effects</strong></p>
<ul>
<li>Insomnia</li>
<li>Sleep disturbances</li>
<li>Somnolence</li>
<li>Sedation</li>
<li>Nausea</li>
<li>GI</li>
<li>Sexual dysfunction</li>
<li>Qt prolongation</li>
<li>Dizziness</li>
<li>Dry mouth</li>
<li>Hyponatremia</li>
</ul>
<p><strong>Additional information</strong></p>
<ul>
<li>May increase QT (doses &gt;40mg/day)</li>
<li>SSRI appears as a class in 2019 AGS Beers Criteria®*</li>
</ul>
</div>
                                      </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead">Third-line treatment</span>
                    <h6>Trazodone</h6>
                    <div class="column">
<p><strong>Level of evidence • •</strong></p>
<p><strong>Adverse effects</strong></p>
<ul>
<li>Nausea</li>
<li>Priapism in men (rare)</li>
<li>Orthostatic hypotension</li>
</ul>
</div>
                                      </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead">Third-line treatment (tetracyclic antidepressant)</span>
                    <h6>Mirtazapine</h6>
                    <div class="column">
<p><strong>Level of evidence </strong><strong>•</strong></p>
<p><strong>Adverse effects</strong></p>
<ul>
<li>Sedation</li>
<li>Increased appetite &amp; weight</li>
<li>Dizziness</li>
<li>Dry mouth</li>
</ul>
</div>
                                      </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead">Third-line treatment (SNRI)</span>
                    <h6>Fluoxetine</h6>
                    <p><strong>Level of evidence </strong><strong>•</strong></p>
<p><strong>Adverse effects</strong></p>
<ul>
<li>Insomnia</li>
<li>Sleep disturbances</li>
<li>Somnolence</li>
<li>Sedation</li>
<li>Nausea</li>
<li>GI</li>
<li>Anorexic &amp; stimulating</li>
<li>Sexual dysfunction</li>
<li>Qt prolongation</li>
<li>Dizziness</li>
<li>Dry mouth</li>
<li>Hyponatremia</li>
</ul>
<p><strong>Additional information</strong></p>
<ul>
<li>SNRI appears as a class in 2019 AGS Beers Criteria®*</li>
<li>Long half-life (5-week washout)</li>
</ul>
                                      </div>
                                  </li>

                      </ul>
        </div>
      </div>
    </div>
</article>

<article class="block--paragraph  core-block" data-block-name="core/paragraph"><div class="container">
<p style="font-size:12px"><em><strong>Notes:</strong> BP= blood pressure, ER= extended release, CR= controlled release, GI= gastrointestinal, SNRIs= serotonin and norepinephrine reuptake inhibitors, SR= sustained release, SSRIs= selective serotonin reuptake inhibitors, XL= extra-long /large</em></p>
</div></article>

<article class="block--paragraph  core-block" data-block-name="core/paragraph"><div class="container">
<p style="font-size:12px"><em>* The Beers Criteria is published by the American Geriatrics Society and is a list of potentially inappropriate medications in older adults. <sup><a href="https://tools.cep.health/tool/managing-benzodiazepine-use-in-older-adults/#references" data-wpel-link="internal">28</a></sup></em></p>
</div></article>

<article class="block--paragraph  core-block" data-block-name="core/paragraph"><div class="container">
<p><em>Level of evidence: </em><br><strong>· · · </strong><em>= meta-analysis or at least 2 randomized controlled trials that included a placebo condition,</em><br><strong>· · </strong><em>= at least 1 randomized controlled trial with placebo or active comparison condition,</em><br><strong>· </strong><em>= uncontrolled trial with at least 10 subjects <br></em></p>
</div></article>						</div>
					</div>
				</section>
							<section class="main-section" id="alternatives-to-benzodiazepines-for-insomnia" tabindex="-1">
					<div class="head">
						<div class="container">
							<h2 class="main-heading">
								Alternatives to Benzodiazepines for Insomnia								
							</h2>
							<div class="icon">
								<svg width="22" height="22" viewBox="0 0 22 22" fill="none" xmlns="http:/ /www.w3.org/2000/svg">
									<path fill-rule="evenodd" clip-rule="evenodd" d="M16 12H6V10H16V12Z" class="horizontal-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M10 16V6H12V16H10Z" class="vertical-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M11 20C15.9706 20 20 15.9706 20 11C20 6.02944 15.9706 2 11 2C6.02944 2 2 6.02944 2 11C2 15.9706 6.02944 20 11 20ZM11 22C17.0751 22 22 17.0751 22 11C22 4.92487 17.0751 0 11 0C4.92487 0 0 4.92487 0 11C0 17.0751 4.92487 22 11 22Z" class="outline" />
								</svg>
							</div>
						</div>
					</div>
					<div class="body">
						<div class="container">
							<article class="block--paragraph  core-block" data-block-name="core/paragraph"><div class="container">
<p class="is-style-default">The following outlines many of the non-pharmacological and pharmacological alternative therapy options to benzodiazepines for older adults, along with the level of evidence and adverse effects associated with each therapy.</p>
</div></article>

<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h3 class="wp-block-heading">Non-pharmacological options</h3>
</div></article>

<article class="block--text-with-icon ">  <div class="container">
    
        <div class="columns is-flex is-gapless">
          <div class="column is-2-mobile is-1">
            <div class="inner">
              <img decoding="async" src="https://tools.cep.health/wp-content/uploads/2019/10/Checkmark-Large-2.svg" />
            </div>
          </div>
          <div class="column is-10-mobile is-11">
            <p>Non-pharmacological alternatives are the preferred treatment for anxiety disorders, insomnia or panic disorder among older adults.</p>
          </div>
        </div>

      </div>
</article>

<article class="block--drug-options ">
<div class="container">
  <h5><span style="font-size: 13.5px;">Scroll (left-right) for details</h5>
          <div class="slider">
        <div class="inner-stage">
          <ul>
            
                <li>
                  <div class="inner">
                    <span class="subhead"></span>
                    <h6>Cognitive behavioural therapy</h6>
                    <p><strong>Level of evidence • • </strong>to <strong>• • •</strong></p>
<p><strong>Notes</strong></p>
<ul>
<li>Cognitive behavioural therapy for insomnia is more effective than pharmacological therapy for the short- and long-term management of insomnia in older adults.<sup>17</sup></li>
<li>Restructures maladaptive beliefs regarding health and daytime consequences of insomnia</li>
</ul>
                                      </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead"></span>
                    <h6>Good sleep hygiene</h6>
                    <p><strong>Level of evidence • •</strong></p>
<p><strong>Notes</strong></p>
<ul>
<li>Reduces behaviours that interfere with sleep drive or increased arousal</li>
</ul>
                                      </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead"></span>
                    <h6>Sleep restriction</h6>
                    <p><strong>Level of evidence • </strong>to <strong>• •</strong></p>
<p><strong>Notes</strong></p>
<ul>
<li>Increases sleep drive and stabilizes circadian rhythm</li>
</ul>
                                      </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead"></span>
                    <h6>Stimulus control</h6>
                    <p><strong>Level of evidence • </strong>to <strong>• •</strong></p>
<p><strong>Notes</strong></p>
<ul>
<li>Reduces arousal in sleep environment and promotes the association between bed and sleep</li>
</ul>
                                      </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead"></span>
                    <h6>Progressive muscle relaxation</h6>
                    <p><strong>Level of evidence • </strong>to <strong>• •</strong></p>
<p><strong>Notes</strong></p>
<ul>
<li>Reduces physical and psychological arousal in sleep environment</li>
</ul>
                                      </div>
                                  </li>

                      </ul>
        </div>
      </div>
    </div>
</article>

<article class="block--paragraph  core-block" data-block-name="core/paragraph"><div class="container">
<p><em>Level of evidence: </em><br><strong>· · · </strong><em>= meta-analysis or at least 2 randomized controlled trials that included a placebo condition, </em><br><strong>· · </strong><em>= at least 1 randomized controlled trial with placebo or active comparison condition,</em><br><strong>· </strong><em>= uncontrolled trial with at least 10 subjects</em></p>
</div></article>

<article class="block--text-with-icon ">  <div class="container">
    
        <div class="columns is-flex is-gapless">
          <div class="column is-2-mobile is-1">
            <div class="inner">
              <img decoding="async" src="https://tools.cep.health/wp-content/uploads/2019/10/Eye.svg" />
            </div>
          </div>
          <div class="column is-10-mobile is-11">
            <p>See <a href="#provider-and-patient-resources">Patient Resources</a> for more information.</p>
          </div>
        </div>

      </div>
</article>

<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h3 class="wp-block-heading" id="zdrugs"><strong>Nonbenzodiazepine benzodiazepine receptor agonist hypnotics (Z-drugs)</strong></h3>
</div></article>

<article class="block--paragraph  core-block" data-block-name="core/paragraph"><div class="container">
<p>Z-drugs have adverse events similar to those of benzodiazepines in older adults (e.g. delirium, falls, fractures, daytime sedation, increased emergency room visits/hospitalizations, motor vehicle crashes and minimal improvement in sleep latency and duration). Z-drugs should be avoided in older adults or those with a history of these adverse events.<sup>28, 35, 36</sup></p>
</div></article>

<article class="block--background  core-block" data-block-name="cep/background"><div class="container">
<div class="wp-block-cep-background is-style-red-background"><article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h6 class="wp-block-heading"><strong>Increased risk: Z-drugs and complex sleep disorders<sup>41</sup></strong></h6>
</div></article>

<article class="block--list  core-block" data-block-name="core/list"><div class="container">
<ul class="wp-block-list">
<li>Serious injuries and death from complex sleep behaviors have occurred in patients who have taken Z-drugs with and without a history of such behaviors, even at the lowest recommended doses, and the behaviors can occur after just 1 dose</li>



<li>Health care professionals should not prescribe Z-drugs to patients who have previously experienced complex sleep behaviors after taking these medications</li>
</ul>
</div></article></div>
</div></article>

<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h4 class="wp-block-heading">Discontinuing Z-drugs<sup>14</sup></h4>
</div></article>

<article class="block--paragraph  core-block" data-block-name="core/paragraph"><div class="container">
<p>Tapering is recommended when discontinuing after use for more than 4 weeks. To help lessen the more common withdrawal symptom of rebound insomnia:</p>
</div></article>

<article class="block--list  core-block" data-block-name="core/list"><div class="container">
<ul class="wp-block-list">
<li>Gradually reduce the dose by 50% every week until lowest available dose is being used, then reduce use to every other day, then use only as needed and then discontinue use completely <strong>OR</strong></li>



<li>Gradually reduce the dose by 25% every 2 weeks and then slow the taper to 12.5% every 2 weeks near the end<sup>7</sup></li>
</ul>
</div></article>

<article class="block--paragraph  core-block" data-block-name="core/paragraph"><div class="container">
<p>Educate the patient that some sleep difficulty should be expected but that it should resolve within a week.</p>
</div></article>

<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h3 class="wp-block-heading">Pharmacological options</h3>
</div></article>

<article class="block--text-with-icon ">  <div class="container">
    
        <div class="columns is-flex is-gapless">
          <div class="column is-2-mobile is-1">
            <div class="inner">
              <img decoding="async" src="https://tools.cep.health/wp-content/uploads/2019/10/Yellow-Notice.svg" />
            </div>
          </div>
          <div class="column is-10-mobile is-11">
            <p>As patients age, their bodies respond to medications differently, making them more susceptible to adverse events and drug-drug interactions. If using pharmacological alternatives in older patients, consider patient factors and use the &#8220;<strong>start low, go slow</strong>&#8221; approach.</p>
          </div>
        </div>

    
        <div class="columns is-flex is-gapless">
          <div class="column is-2-mobile is-1">
            <div class="inner">
              <img decoding="async" src="https://tools.cep.health/wp-content/uploads/2020/05/stop.svg" />
            </div>
          </div>
          <div class="column is-10-mobile is-11">
            <p>There are no medications for primary or chronic insomnia in older adults that are proven to be safe and effective.<sup>7</sup></p>
          </div>
        </div>

      </div>
</article>

<article class="block--drug-options ">
<div class="container">
  <h5><span style="font-size: 13.5px;">Scroll (left-right) for details</h5>
          <div class="slider">
        <div class="inner-stage">
          <ul>
            
                <li>
                  <div class="inner">
                    <span class="subhead">Z-drug</span>
                    <h6>Zopiclone</h6>
                    <p><strong>Level of evidence •</strong> to <strong>• •</strong></p>
<p><strong>Covered by Exceptional Access Program<sup>39</sup></strong></p>
<p><strong>Formulations</strong></p>
<ul>
<li>3.75mg, 5mg, 7.5mg ^</li>
<li>Older patient max: 5mg/day</li>
</ul>
<p><strong>Notes</strong></p>
<ul>
<li>Indicated for insomnia but avoid in older adults<sup>28</sup></li>
<li>Improves sleep onset latency (~19 min), total sleep time (~45 min), wake after sleep onset (~11 min)</li>
<li>Risk of physical tolerance and dependence</li>
</ul>
                                      </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead">Z-drug</span>
                    <h6>Zolpidem</h6>
                    <p><strong>Level of evidence •</strong> to <strong>• •</strong></p>
<p><strong>Possibly covered by Exceptional Access Program<sup>40</sup></strong></p>
<p><strong>Formulations</strong></p>
<ul>
<li>5mg, 10mg</li>
<li>Older patient max: 5mg/day</li>
</ul>
<p><strong>Notes</strong></p>
<ul>
<li>Indicated for insomnia but avoid in older adults<sup>28</sup></li>
<li>Improves sleep onset latency (~15 min), total sleep time (~23 min)</li>
<li>Oral disintegrating tablet – cannot be split</li>
<li>Less chance of morning hang-over effect than zopiclone</li>
<li>Risk of physical tolerance and dependence</li>
</ul>
                                      </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead">Tricyclic antidepressant</span>
                    <h6>Doxepin</h6>
                    <p><strong>Level of evidence • </strong>to <strong>• •</strong></p>
<p><strong>Adverse effects</strong></p>
<ul>
<li>Anticholinergic side effects with higher dose</span></li>
</ul>
<p><strong>Notes</strong></p>
<ul>
<li>Appears in 2019 AGS Beers Criteria®* (for doses greater than 6mg)</li>
<li>3mg: improves total sleep time (~12 min), wake after sleep onset (~10 min)</li>
<li>6mg: improves total sleep time (~17 min), wake after sleep onset (~14 min)</li>
<li>Not to be taken within 3 hours of a meal due to delayed absorption and the potential for next day drowsiness</li>
<li>Minimal risk of physical tolerance/dependence; consider doxepin if substance abuse or dependence is a concern</li>
</ul>
                                      </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead"></span>
                    <h6>Trazodone</h6>
                    <p><strong>Level of evidence • </strong>to <strong>• •</strong></p>
<p><strong>Adverse effects</strong></p>
<ul>
<li>Orthostatic hypotension</span></li>
<li>Priapism in men (rare)</li>
</ul>
<p><strong>Notes</strong></p>
<ul>
<li>Trazodone is indicated for depression; limited evidence for insomnia</span></li>
<li>Lower risk of morning hangover effect due to a short half-life</span></li>
<li>Minimal risk of tolerance/dependence</li>
<li>Low anticholinergic activity</li>
</ul>
                                      </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead"></span>
                    <h6>Melatonin</h6>
                    <p><strong>Level of evidence • </strong>to <strong>• •</strong></p>
<p><strong>Adverse effects</strong></p>
<ul>
<li>Fatigue</span></li>
<li>Headache</li>
<li>Dizziness</li>
<li>Irritability</li>
<li>Abdominal cramps</li>
</ul>
<p><strong>Notes</strong></p>
<ul>
<li>Modest effect on sleep (may decrease sleep onset latency [~7 min]; increases total sleep time [~8 min], and improves sleep quality)</span></li>
<li>No apparent physical tolerance and dependence</li>
<li>Purity concerns</li>
</ul>
                                      </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead"></span>
                    <h6>Valerian root</h6>
                    <p><strong>Level of evidence • </strong>to <strong>• •</strong></p>
<p><strong>Adverse effects</strong></p>
<ul>
<li>Headache</li>
<li>Dizziness</li>
<li>Nausea</li>
<li>Upset stomach</li>
<li>Hepatotoxicity (rare)</li>
</ul>
<p><strong>Notes</strong></p>
<ul>
<li>Limited evidence for insomnia</li>
<li>Purity concerns</li>
</ul>
                                      </div>
                                  </li>

                      </ul>
        </div>
      </div>
    </div>
</article>

<article class="block--paragraph  core-block" data-block-name="core/paragraph"><div class="container">
<p style="font-size:12px"><strong> Notes</strong>: TCA= tricyclic antidepressant, Z-drugs= non-benzodiazepine benzodiazepine receptor agonist hypnotics</p>
</div></article>

<article class="block--paragraph  core-block" data-block-name="core/paragraph"><div class="container">
<p style="font-size:12px"><em>• the Beers Criteria is published by the American Geriatrics Society and is a list of potentially inappropriate medications in older adults<sup>28</sup></em><br><em>^ Scored</em></p>
</div></article>

<article class="block--paragraph  core-block" data-block-name="core/paragraph"><div class="container">
<p><em>Level of evidence: </em><br><strong>· · · </strong><em>= meta-analysis or at least 2 randomized controlled trials that included a placebo condition, </em><br><strong>· · </strong><em>= at least 1 randomized controlled trial with placebo or active comparison condition,</em><br><strong>· </strong><em>= uncontrolled trial with at least 10 subjects</em></p>
</div></article>

<article class="block--background  core-block" data-block-name="cep/background"><div class="container">
<div class="wp-block-cep-background is-style-red-background"><article class="block--faq "><div class="container">
    <div class="faq-title-wrapper">
        <div class="faq-icon-wrapper">
            <img decoding="async" class="faq-icon" src="https://tools.cep.health/wp-content/uploads/2020/05/stop.svg" alt="" />
        </div>
        <h3 class="faq-title"><h4>Medications not recommended for the sole management of insomnia:<sup>21, 29</sup></h4></h3>
    </div>
            <div class="questions">
                                                                <div class="question">
                        <button data-toggle-question class="question-title-wrapper">
                            <h6 class="question-title">Mirtazapine, fluvoxamine (SSRIs) and amitriptyline (TCA)</h6>
							<div class="icon">
								<svg width="22" height="22" viewBox="0 0 22 22" fill="none" xmlns="http:/ /www.w3.org/2000/svg">
									<path fill-rule="evenodd" clip-rule="evenodd" d="M16 12H6V10H16V12Z" class="horizontal-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M10 16V6H12V16H10Z" class="vertical-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M11 20C15.9706 20 20 15.9706 20 11C20 6.02944 15.9706 2 11 2C6.02944 2 2 6.02944 2 11C2 15.9706 6.02944 20 11 20ZM11 22C17.0751 22 22 17.0751 22 11C22 4.92487 17.0751 0 11 0C4.92487 0 0 4.92487 0 11C0 17.0751 4.92487 22 11 22Z" class="outline" />
								</svg>
							</div>
                        </button>
                        <div class="question-answer">
                            <p><strong>Adverse effects</strong></p>
<ul>
<li>Anticholinergic</li>
<li>Sedation</li>
<li>Somnolence</li>
<li>GI</li>
<li>Headache</li>
</ul>
<p><strong>Notes</strong></p>
<ul>
<li>Relative lack of evidence</li>
<li>Significant adverse effects</li>
</ul>
                        </div>
                    </div>
                                                                                <div class="question">
                        <button data-toggle-question class="question-title-wrapper">
                            <h6 class="question-title">Antihistamine</h6>
							<div class="icon">
								<svg width="22" height="22" viewBox="0 0 22 22" fill="none" xmlns="http:/ /www.w3.org/2000/svg">
									<path fill-rule="evenodd" clip-rule="evenodd" d="M16 12H6V10H16V12Z" class="horizontal-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M10 16V6H12V16H10Z" class="vertical-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M11 20C15.9706 20 20 15.9706 20 11C20 6.02944 15.9706 2 11 2C6.02944 2 2 6.02944 2 11C2 15.9706 6.02944 20 11 20ZM11 22C17.0751 22 22 17.0751 22 11C22 4.92487 17.0751 0 11 0C4.92487 0 0 4.92487 0 11C0 17.0751 4.92487 22 11 22Z" class="outline" />
								</svg>
							</div>
                        </button>
                        <div class="question-answer">
                            <p><strong>Adverse effects</strong></p>
<ul>
<li>Anticholinergic</li>
<li>Cognitive Impairment</li>
<li>Extrapyramidal reactions</li>
<li>Hypotension</li>
</ul>
<p><strong>Notes</strong></p>
<ul>
<li>Lack of evidence or excessive risk of daytime sedation, psychomotor impairment and anticholinergic activity</li>
</ul>
                        </div>
                    </div>
                                                                                <div class="question">
                        <button data-toggle-question class="question-title-wrapper">
                            <h6 class="question-title">Antinauseants</h6>
							<div class="icon">
								<svg width="22" height="22" viewBox="0 0 22 22" fill="none" xmlns="http:/ /www.w3.org/2000/svg">
									<path fill-rule="evenodd" clip-rule="evenodd" d="M16 12H6V10H16V12Z" class="horizontal-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M10 16V6H12V16H10Z" class="vertical-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M11 20C15.9706 20 20 15.9706 20 11C20 6.02944 15.9706 2 11 2C6.02944 2 2 6.02944 2 11C2 15.9706 6.02944 20 11 20ZM11 22C17.0751 22 22 17.0751 22 11C22 4.92487 17.0751 0 11 0C4.92487 0 0 4.92487 0 11C0 17.0751 4.92487 22 11 22Z" class="outline" />
								</svg>
							</div>
                        </button>
                        <div class="question-answer">
                            <p><strong>Adverse effects</strong></p>
<ul>
<li>Anticholinergic</li>
<li>Sedation</li>
<li>Somnolence</li>
<li>Cognitive Impairment</li>
</ul>
<p><strong>Notes</strong></p>
<ul>
<li>Lack of evidence or excessive risk of daytime sedation, psychomotor impairment and anticholinergic activity</li>
</ul>
                        </div>
                    </div>
                                                                                <div class="question">
                        <button data-toggle-question class="question-title-wrapper">
                            <h6 class="question-title">Antipsychotics (conventional or atypical)</h6>
							<div class="icon">
								<svg width="22" height="22" viewBox="0 0 22 22" fill="none" xmlns="http:/ /www.w3.org/2000/svg">
									<path fill-rule="evenodd" clip-rule="evenodd" d="M16 12H6V10H16V12Z" class="horizontal-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M10 16V6H12V16H10Z" class="vertical-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M11 20C15.9706 20 20 15.9706 20 11C20 6.02944 15.9706 2 11 2C6.02944 2 2 6.02944 2 11C2 15.9706 6.02944 20 11 20ZM11 22C17.0751 22 22 17.0751 22 11C22 4.92487 17.0751 0 11 0C4.92487 0 0 4.92487 0 11C0 17.0751 4.92487 22 11 22Z" class="outline" />
								</svg>
							</div>
                        </button>
                        <div class="question-answer">
                            <p><strong>Adverse effects</strong></p>
<ul>
<li>Anticholinergic</li>
<li>Sedation</li>
<li>Extrapyramidal reactions</li>
<li>Weight gain</li>
</ul>
<p><strong>Notes</strong></p>
<ul>
<li>Lack of evidence</li>
<li>Risk of anticholinergic and neurological toxicity (conventional)and metabolic toxicity (atypicals)</li>
<li>Possible increased risk of stroke/mortality in patients with behavioural and psychological symptoms of dementia (NNH = 100 in 12 weeks)</li>
</ul>
                        </div>
                    </div>
                                                                                <div class="question">
                        <button data-toggle-question class="question-title-wrapper">
                            <h6 class="question-title">Muscle relaxants</h6>
							<div class="icon">
								<svg width="22" height="22" viewBox="0 0 22 22" fill="none" xmlns="http:/ /www.w3.org/2000/svg">
									<path fill-rule="evenodd" clip-rule="evenodd" d="M16 12H6V10H16V12Z" class="horizontal-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M10 16V6H12V16H10Z" class="vertical-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M11 20C15.9706 20 20 15.9706 20 11C20 6.02944 15.9706 2 11 2C6.02944 2 2 6.02944 2 11C2 15.9706 6.02944 20 11 20ZM11 22C17.0751 22 22 17.0751 22 11C22 4.92487 17.0751 0 11 0C4.92487 0 0 4.92487 0 11C0 17.0751 4.92487 22 11 22Z" class="outline" />
								</svg>
							</div>
                        </button>
                        <div class="question-answer">
                            <p><strong>Adverse effects</strong></p>
<ul>
<li>Somnolence</li>
<li>Impaired function</li>
<li>Falls</li>
<li>Dependence</li>
</ul>
<p><strong>Notes</strong></p>
<ul>
<li>Lack of evidence and risk of central nervous system effects</li>
</ul>
                        </div>
                    </div>
                                                                                <div class="question">
                        <button data-toggle-question class="question-title-wrapper">
                            <h6 class="question-title">Pregabalin, gabapentin</h6>
							<div class="icon">
								<svg width="22" height="22" viewBox="0 0 22 22" fill="none" xmlns="http:/ /www.w3.org/2000/svg">
									<path fill-rule="evenodd" clip-rule="evenodd" d="M16 12H6V10H16V12Z" class="horizontal-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M10 16V6H12V16H10Z" class="vertical-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M11 20C15.9706 20 20 15.9706 20 11C20 6.02944 15.9706 2 11 2C6.02944 2 2 6.02944 2 11C2 15.9706 6.02944 20 11 20ZM11 22C17.0751 22 22 17.0751 22 11C22 4.92487 17.0751 0 11 0C4.92487 0 0 4.92487 0 11C0 17.0751 4.92487 22 11 22Z" class="outline" />
								</svg>
							</div>
                        </button>
                        <div class="question-answer">
                            <p><strong>Adverse effects</strong></p>
<ul>
<li>Somnolence</li>
<li>GI</li>
<li>Weight gain</li>
<li>Edema</li>
</ul>
<p><strong>Notes</strong></p>
<ul>
<li>Lack of evidence</li>
</ul>
                        </div>
                    </div>
                                    </div>
    </div></article></div>
</div></article>						</div>
					</div>
				</section>
							<section class="main-section" id="alternatives-to-benzodiazepines-for-panic-disorders" tabindex="-1">
					<div class="head">
						<div class="container">
							<h2 class="main-heading">
								Alternatives to Benzodiazepines for Panic Disorders								
    <span class="badge new" data-last-modified="Jul 18, 2024" data-hide-on-click>New</span>
							</h2>
							<div class="icon">
								<svg width="22" height="22" viewBox="0 0 22 22" fill="none" xmlns="http:/ /www.w3.org/2000/svg">
									<path fill-rule="evenodd" clip-rule="evenodd" d="M16 12H6V10H16V12Z" class="horizontal-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M10 16V6H12V16H10Z" class="vertical-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M11 20C15.9706 20 20 15.9706 20 11C20 6.02944 15.9706 2 11 2C6.02944 2 2 6.02944 2 11C2 15.9706 6.02944 20 11 20ZM11 22C17.0751 22 22 17.0751 22 11C22 4.92487 17.0751 0 11 0C4.92487 0 0 4.92487 0 11C0 17.0751 4.92487 22 11 22Z" class="outline" />
								</svg>
							</div>
						</div>
					</div>
					<div class="body">
						<div class="container">
							<article class="block--paragraph  core-block" data-block-name="core/paragraph"><div class="container">
<p class="is-style-default">The following outlines many of the non-pharmacological and pharmacological alternative therapy options to benzodiazepines for older adults, along with the level of evidence and adverse effects associated with each therapy. </p>
</div></article>

<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h3 class="wp-block-heading">Non-pharmacological options</h3>
</div></article>

<article class="block--text-with-icon ">  <div class="container">
    
        <div class="columns is-flex is-gapless">
          <div class="column is-2-mobile is-1">
            <div class="inner">
              <img decoding="async" src="https://tools.cep.health/wp-content/uploads/2019/10/Checkmark-Large-2.svg" />
            </div>
          </div>
          <div class="column is-10-mobile is-11">
            <p>Non-pharmacological alternatives are the preferred treatment for anxiety disorders, insomnia or panic disorder among older adults.</p>
          </div>
        </div>

      </div>
</article>

<article class="block--drug-options ">
<div class="container">
  <h5><span style="font-size: 13.5px;">Scroll (left-right) for details</h5>
          <div class="slider">
        <div class="inner-stage">
          <ul>
            
                <li>
                  <div class="inner">
                    <span class="subhead"></span>
                    <h6>Cognitive behavioural therapy</h6>
                    <p><strong>Level of evidence </strong><strong>• • •</strong></p>
<p><strong>Notes</strong></p>
<ul>
<li>Cognitive behavioural therapy as the initial treatment for panic disorder is strongly supported by demonstrated efficacy in numerous randomized controlled trials <sup>4</sup></li>
</ul>
                                      </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead"></span>
                    <h6>Daily diary</h6>
                    <p><strong>Level of evidence </strong><strong>• • •</strong></p>
<p><strong>Notes</strong></p>
<ul>
<li>Allows for monitoring of panic symptoms to gather information about the association between internal stimuli (e.g. emotions) and external stimuli (e.g. substances, particular situations or settings)</li>
</ul>
                                      </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead"></span>
                    <h6>Patient education</h6>
                    <p><strong>Level of evidence </strong><strong>• • •</strong></p>
<p><strong>Notes</strong></p>
<ul>
<li>To reassure the patient that their symptoms are not life-threatening and that panic disorders are common (i.e. they are not alone)</li>
<li>Should include general promotion of healthy behaviours (e.g. good nutrition, exercise, good sleep hygiene) as well as decreased used of caffeine, tobacco, alcohol and other potentially deleterious substances</li>
</ul>
                                      </div>
                                  </li>

                      </ul>
        </div>
      </div>
    </div>
</article>

<article class="block--paragraph  core-block" data-block-name="core/paragraph"><div class="container">
<p><em>Level of evidence:</em><br><strong>· · · </strong><em>= meta-analysis or at least 2 randomized controlled trials that included a placebo condition,</em><br><strong>· · </strong><em>= at least 1 randomized controlled trial with placebo or active comparison condition,</em><br><strong>· </strong><em>= uncontrolled trial with at least 10 subjects</em></p>
</div></article>

<article class="block--text-with-icon ">  <div class="container">
    
        <div class="columns is-flex is-gapless">
          <div class="column is-2-mobile is-1">
            <div class="inner">
              <img decoding="async" src="https://tools.cep.health/wp-content/uploads/2019/10/Eye.svg" />
            </div>
          </div>
          <div class="column is-10-mobile is-11">
            <p>See <a href="#provider-and-patient-resources">Patient Resources</a> for more information.</p>
          </div>
        </div>

      </div>
</article>

<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h5 class="wp-block-heading">Pharmacological options</h5>
</div></article>

<article class="block--text-with-icon ">  <div class="container">
    
        <div class="columns is-flex is-gapless">
          <div class="column is-2-mobile is-1">
            <div class="inner">
              <img decoding="async" src="https://tools.cep.health/wp-content/uploads/2019/10/Yellow-Notice.svg" />
            </div>
          </div>
          <div class="column is-10-mobile is-11">
            <p>As patients age, their bodies respond to medications differently, making them more susceptible to adverse events and drug-drug interactions. If using pharmacological alternatives in older patients, consider patient factors and use the &#8220;<strong>start low, go slow</strong>&#8221; approach.</p>
<p>If pharmacotherapy is used, use lower starting and therapeutic doses and a slower dose titration of medication than those used for younger patients.<sup>4</sup></p>
          </div>
        </div>

      </div>
</article>

<article class="block--drug-options ">
<div class="container">
  <h5><span style="font-size: 13.5px;">Scroll (left-right) for details</h5>
          <div class="slider">
        <div class="inner-stage">
          <ul>
            
                <li>
                  <div class="inner">
                    <span class="subhead">First-line treatment</span>
                    <h6>Citalopram, escitalopram, fluoxetine, fluvoxamine and sertraline (SSRIs)</h6>
                    <p><strong>Level of evidence • • •</strong></p>
<p><strong>Adverse effects</strong></p>
<ul>
<li>Insomnia</li>
<li>Somnolence</li>
<li>Nausea</li>
<li>GI</li>
<li>Weight gain</li>
<li>Sexual dysfunction</li>
<li>Qt prolongation</li>
<li>Hyponatremia</li>
<li>Dry mouth</li>
<li>Dizziness</li>
</ul>
<p><strong>Notes</strong></p>
<ul>
<li>SSRI appears as a class in 2019 AGS Beers Criteria®*</li>
<li>Few drug interactions</li>
</ul>
                                      </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead">Second-line treament</span>
                    <h6>Mirtazapine</h6>
                    <p><strong>Level of evidence • •</strong></p>
<p><strong>Adverse effects</strong></p>
<ul>
<li>Sedation</li>
<li>Increased appetite</li>
<li>Weight gain</li>
<li>Dry mouth</li>
<li>Dizziness</li>
<li>Edema</li>
</ul>
<p><strong>Notes</strong></p>
<ul>
<li>SSRI appears as a class in 2019 AGS Beers Criteria®*</li>
</ul>
<p>&nbsp;</p>
                                      </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead">Second-line treatment</span>
                    <h6>Clomipramine and imipramine (TCAs)</h6>
                    <p><strong>Level of evidence • • •</strong></p>
<p><strong>Adverse effects</strong></p>
<ul>
<li>Somnolence</li>
<li>Increased appetite</li>
<li>Weight gain</li>
<li>Suicidal Ideation</li>
<li>Confusion</li>
<li>Qt prolongation</li>
<li>Agitation</li>
<li>Dry mouth</li>
</ul>
<p><strong>Notes</strong></p>
<ul>
<li>Appears in 2019 AGS Beers Criteria®*</li>
<li>Caution due to anticholinergic and cardiovascular side effects</li>
</ul>
                                      </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead">Third-line treatment</span>
                    <h6>Duloxetine (SNRI)</h6>
                    <p><strong>Level of evidence •</strong></p>
<p><strong>Adverse effects</strong></p>
<ul>
<li>Sleep disturbances</li>
<li>Nausea</li>
<li>GI</li>
<li>Decreased appetite</li>
<li>Dry mouth</li>
<li>Dizziness</li>
<li>Increased BP</li>
</ul>
                                      </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead">Third-line treatment</span>
                    <h6>Bupropion SR</h6>
                    <p><strong>Level of evidence •</strong></p>
<p><strong>Adverse effects</strong></p>
<ul>
<li>Insomnia</li>
<li>GI</li>
<li>Decreased appetite</li>
<li>Increased seizure activity</li>
</ul>
                                      </div>
                                  </li>

            
                <li>
                  <div class="inner">
                    <span class="subhead">Third-line treatment</span>
                    <h6>Gabapentin</h6>
                    <p><strong>Level of evidence • •</strong></p>
<p><strong>Adverse effects</strong></p>
<ul>
<li>Somnolence</li>
<li>Sedation</li>
<li>GI</li>
<li>Dizziness</li>
<li>Edema</li>
</ul>
<p><strong>Notes</strong></p>
<ul>
<li>Appears in 2019 AGS Beers Criteria®*</li>
</ul>
                                      </div>
                                  </li>

                      </ul>
        </div>
      </div>
    </div>
</article>

<article class="block--paragraph  core-block" data-block-name="core/paragraph"><div class="container">
<p style="font-size:12px"><em><strong>Notes:</strong> BP= blood pressure, GI= gastrointestinal, SNRIs= serotonin and norepinephrine reuptake inhibitors, SR= sustained release, SSRIs= selective serotonin reuptake inhibitors, TCAs= tricyclic antidepressants</em></p>
</div></article>

<article class="block--paragraph  core-block" data-block-name="core/paragraph"><div class="container">
<p style="font-size:12px"><em>* The Beers Criteria is published by the American Geriatrics Society and is a list of potentially inappropriate medications in older adults. <sup>28</sup></em><br></p>
</div></article>

<article class="block--paragraph  core-block" data-block-name="core/paragraph"><div class="container">
<p><em>Level of evidence:</em><br><strong>· · · </strong><em>= meta-analysis or at least 2 randomized controlled trials that included a placebo condition,</em><br><strong>· · </strong><em>= at least 1 randomized controlled trial with placebo or active comparison condition,</em><br><strong>· </strong><em>= uncontrolled trial with at least 10 subjects</em></p>
</div></article>						</div>
					</div>
				</section>
							<section class="main-section" id="provider-and-patient-resources" tabindex="-1">
					<div class="head">
						<div class="container">
							<h2 class="main-heading">
								Provider and Patient Resources								
							</h2>
							<div class="icon">
								<svg width="22" height="22" viewBox="0 0 22 22" fill="none" xmlns="http:/ /www.w3.org/2000/svg">
									<path fill-rule="evenodd" clip-rule="evenodd" d="M16 12H6V10H16V12Z" class="horizontal-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M10 16V6H12V16H10Z" class="vertical-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M11 20C15.9706 20 20 15.9706 20 11C20 6.02944 15.9706 2 11 2C6.02944 2 2 6.02944 2 11C2 15.9706 6.02944 20 11 20ZM11 22C17.0751 22 22 17.0751 22 11C22 4.92487 17.0751 0 11 0C4.92487 0 0 4.92487 0 11C0 17.0751 4.92487 22 11 22Z" class="outline" />
								</svg>
							</div>
						</div>
					</div>
					<div class="body">
						<div class="container">
							<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h3 class="wp-block-heading">For providers</h3>
</div></article>

<article class="block--support-materials ">

  <div class="container wide">
    <div class="inner">
              <div class="columns">
                      <div class="column icon">
              <img decoding="async" src="https://tools.cep.health/wp-content/themes/cep-tools/img/support-materials.svg" />
            </div>
                                <div class="column">
              <strong class="heading"><h6>Decision support tools and resources</h6></strong>
            </div>
                  </div>
                    <div class="columns">
                      <div class="column">
              <ul>
<li><a href="https://link.cep.health/benzohtml1" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">Centre for Effective Practice increased risk patient postcard</a></li>
<li><a href="https://link.cep.health/benzohtml2" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">Canadian Deprescribing Network (CaDeN) useful patient resources</a></li>
<li><a href="https://link.cep.health/benzohtml5" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">The Ashton Manual</a> benzodiazepines tapering approaches</li>
<li><a href="https://link.cep.health/benzohtml41" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">College of Physicians and Surgeons of Alberta benzodiazepine treatment agreement</a></li>
<li><a href="https://link.cep.health/benzohtml10" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">GeriMedRisk</a> telemedicine (telephone and eConsult) consultation service for questions regarding medication use in older adult patients from a team of geriatric specialists and pharmacists</li>
<li><a href="https://link.cep.health/benzohtml11" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">Centre for Effective Practice Management of chronic insomnia tool</a></li>
<li><a href="https://link.cep.health/benzohtml12" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">iAM Medical Guidelines deprescribing.org app</a></li>
<li><a href="https://link.cep.health/benzohtml13" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">Ontario Drug Benefit formulary search</a></li>
<li><a href="https://link.cep.health/benzohtml14" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">2019 AGS Beers Criteria®</a> list of potentially inappropriate medications in older adults published by the by the American Geriatrics Society</li>
</ul>
            </div>
                            </div>
          </div>
  </div>

</article>

<article class="block--heading  core-block" data-block-name="core/heading"><div class="container">
<h3 class="wp-block-heading">For patients</h3>
</div></article>

<article class="block--file-download ">
<div class="container">
  <a href="https://tools.cep.health/wp-content/uploads/2020/09/Benzo-Patient-Resource.pdf" download="" target="_blank" class="inner" data-wpel-link="internal">
    <div class="inner-wrapper">
      <img decoding="async" src="https://tools.cep.health/wp-content/themes/cep-tools/img/file.svg" />
      <div class="filename-wrapper">
        <h6>Patient resources handout</h6>
        <span class="filename">Benzo-Patient-Resource.pdf</span>
      </div>
    </div>
    <span class="button" target="_blank"><i class="icon-arrow-down-circ"></i> Download</span>
  </a>
</div>
</article>

<article class="block--support-materials ">
  <div class="container two-column">
    <div class="columns is-variable is-8">

      <div class="column">
        <div class="inner">
                      <div class="columns is-variable is-3">
                              <div class="column icon">
                  <img decoding="async" src="https://tools.cep.health/wp-content/themes/cep-tools/img/support-materials.svg" />
                </div>
                                            <div class="column">
                  <strong class="heading"><h6>For patients with anxiety disorders and/or panic disorders</h6></strong>
                </div>
                          </div>
                    <p><strong>Independent cognitive behavioural therapy (book, online, and mobile app)</strong></p>
<ul>
<li><a href="https://link.cep.health/benzohtml15" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">Mind Over Mood</a>: A cognitive behavioural therapy hard copy workbook that provides instruction for how to manage anxiety disorders, panic disorder and other mood problems. Cost is $29.64 USD.</li>
<li><a href="https://link.cep.health/benzohtml16" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">BounceBack Ontario</a>: Guided self-help program grounded in cognitive behavioural therapy designed to help adults manage symptoms of anxiety (and depression). Involves 6 telephone sessions with trained coaches who lead the patient through a series of workbooks. Cost is free. Patient is contacted within 5 business days of referral to schedule first appointment. Referral or patient self-referral is required.</li>
<li><a href="https://link.cep.health/benzohtml17" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">FearFighter — CCBT</a>: A 9-week cognitive behavioural therapy for anxiety and panic disorders mobile app. Provided by Magellan Health Services Inc. Cost is free.</li>
<li><a href="https://link.cep.health/benzohtml18" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">Moodgym</a>: A 5-session online cognitive behavioural therapy program for anxiety (and depression). Cost is $39 AUD for 12 month access.</li>
<li><a href="https://link.cep.health/benzohtml39" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">Centre for Mindfulness Studies</a>: Provides mindfulness-based cognitive therapy, mindfulness-based stressed reduction, mindful self-compas- sion and specialized mindfulness training to the general public, healthcare providers and social service professionals.</li>
</ul>
<p><strong>Progressive muscle relaxation for anxiety</strong></p>
<ul>
<li><a href="https://link.cep.health/benzohtml30" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">Progressive muscle relaxation instructions</a>: Free online/printable instructions for patients on how to conduct progressive muscle relaxation.</li>
</ul>
<p><strong>Daily Diary</strong></p>
<ul>
<li><a href="https://link.cep.health/benzohtml37" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">Worry diary</a>: Free online/printable template for patients to use to keep track of their panic symptoms.</li>
</ul>
        </div>
      </div>
  
      <div class="column">
        <div class="inner">
                      <div class="columns is-variable is-3">
                              <div class="column icon">
                  <img decoding="async" src="https://tools.cep.health/wp-content/themes/cep-tools/img/support-materials.svg" />
                </div>
                                            <div class="column">
                  <strong class="heading"><h6>For patients with insomnia</h6></strong>
                </div>
                          </div>
                    <p><strong>Independent cognitive behavioural therapy (book, online, and mobile app)</strong></p>
<ul>
<li><a href="https://link.cep.health/benzohtml19" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">Sink into Sleep</a>: A 6-step cognitive behavioural therapy hard copy workbook that provides instruction for how to manage insomnia. Cost is $23.58 CAD.</li>
<li><a href="https://link.cep.health/benzohtml20" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">CBT-i Coach</a>: Cognitive behavioural therapy for insomnia mobile app. Provided by the US Department of Veterans Affairs. Cost is free.</li>
<li><span style="font-size: 1.5rem;"><a href="https://link.cep.health/benzohtml21" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">Restore CBT-I</a>: A 6-week cognitive behavioural therapy for insomnia mobile app. Provided by Magellan Health Services Inc. Cost is free.Re</span></li>
<li><span style="font-size: 1.5rem;"><a href="https://link.cep.health/benzohtml42" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">Go! To Sleep</a>: A 6-week cognitive behavioural therapy for insomnia online and mobile app program. Provided by the Cleveland Clinic of Well- ness. Cost is $3.99 USD for app or $40 USD for online.</span></li>
<li><a href="https://link.cep.health/benzohtml23" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">CBT for Insomnia</a>: A 5-session online cognitive behavioural therapy program for insomnia. Cost ranges from $24.95 USD to $49.95 USD.</li>
<li><a href="https://link.cep.health/benzohtml24" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">Sleep Training System</a>: A 6-week online cognitive behavioural therapy for insomnia program with money-back guarantee and personalized feedback. Cost is $29.95 USD.</li>
<li><a href="https://link.cep.health/benzohtml25" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">Sleepio</a>: Cognitive behavioural therapy for insomnia online and mobile app program. Cost is $300 USD for a 12-month subscription.</li>
</ul>
<p><strong>Good Sleep Hygiene, sleep Restrictions, Stimulus Control and Progressive Muscle Relaxation</strong></p>
<ul>
<li><a href="https://link.cep.health/benzohtml35" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">Sleepwell</a>: Free online supports for sleep, including sleep hygiene checklist, instructions for sleep restriction instructions, stimulus control and progressive muscle relaxation as well as sleep diaries and sleep calculators.</li>
</ul>
<p><strong>Daily Diary</strong></p>
<ul>
<li><a href="https://link.cep.health/benzohtml43" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">Sleep Diary</a>: Free online/printable template for patients to use to keep track of their daily sleep patterns.</li>
</ul>
        </div>
      </div>

    </div>
  </div>
</article>

<article class="block--support-materials ">
  <div class="container two-column">
    <div class="columns is-variable is-8">

      <div class="column">
        <div class="inner">
                      <div class="columns is-variable is-3">
                              <div class="column icon">
                  <img decoding="async" src="https://tools.cep.health/wp-content/themes/cep-tools/img/support-materials.svg" />
                </div>
                                            <div class="column">
                  <strong class="heading"><h6>For patients: general psychological therapy</h6></strong>
                </div>
                          </div>
                    <p><strong>In-person cognitive behavioural therapy</strong></p>
<ul>
<li><a href="https://link.cep.health/benzohtml26" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">Canadian Association of Cognitive and Behavioural Therapy — Find a certified therapist webpage</a>: Online search tool to find a certified therapist who provides cognitive behavioural therapy in Canada.</li>
</ul>
<p><strong>Other psychological therapy</strong></p>
<ul>
<li><a href="https://link.cep.health/benzohtml27" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">Big White Wall</a>: Online mental health and wellbeing service offering online peer support and self-management tool. This anonymous service is funded by the government, is available 24 hours a day and has no wait times. Cost is free. No referral needed; valid Ontario postal code required.</li>
<li><a href="https://link.cep.health/benzohtml28" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">Ontario Psychological Association — Find a psychologist search webpage</a>: Online search tool to find a psychologist or psychological associate in Ontario.</li>
<li><a href="https://link.cep.health/benzohtml29" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">PsychologyToday—Find a therapist webpage</a>: Online search tool to find a therapist.</li>
</ul>
        </div>
      </div>
  
      <div class="column">
        <div class="inner">
                      <div class="columns is-variable is-3">
                              <div class="column icon">
                  <img decoding="async" src="https://tools.cep.health/wp-content/themes/cep-tools/img/support-materials.svg" />
                </div>
                                            <div class="column">
                  <strong class="heading"><h6>For patients: physical activity</h6></strong>
                </div>
                          </div>
                    <p><strong>Physical activity</strong></p>
<ul>
<li><a href="https://link.cep.health/benzohtml31" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">Exercise prescription</a>: Free online/printable patient take-home prescription for aerobic activity or strength training.</li>
<li><a href="https://link.cep.health/benzohtml32" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">Tips to get active</a>: Free online/printable physical activity tips for older adults.</li>
<li><a href="https://link.cep.health/benzohtml44" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">Seniors Active Living Centres</a>: Seniors Active Living Centres locations</li>
<li><a href="https://link.cep.health/benzohtml34" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">YMCA</a>: List of in-person YMCA locations across Ontario (senior membership approximately $50/month for individuals or $77/month for couples).</li>
</ul>
        </div>
      </div>

    </div>
  </div>
</article>						</div>
					</div>
				</section>
							<section class="main-section" id="references" tabindex="-1">
					<div class="head">
						<div class="container">
							<h2 class="main-heading">
								References								
							</h2>
							<div class="icon">
								<svg width="22" height="22" viewBox="0 0 22 22" fill="none" xmlns="http:/ /www.w3.org/2000/svg">
									<path fill-rule="evenodd" clip-rule="evenodd" d="M16 12H6V10H16V12Z" class="horizontal-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M10 16V6H12V16H10Z" class="vertical-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M11 20C15.9706 20 20 15.9706 20 11C20 6.02944 15.9706 2 11 2C6.02944 2 2 6.02944 2 11C2 15.9706 6.02944 20 11 20ZM11 22C17.0751 22 22 17.0751 22 11C22 4.92487 17.0751 0 11 0C4.92487 0 0 4.92487 0 11C0 17.0751 4.92487 22 11 22Z" class="outline" />
								</svg>
							</div>
						</div>
					</div>
					<div class="body">
						<div class="container">
							<article class="block--references ">
<div class="container">

                        <ul>
               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [1]
                    </div>

                    <div class="column">
                      <div class="page" title="Page 12">
<div class="layoutArea">
<div class="column">
<p>National Institute for Health and Care Excellence (NICE). Generalized anxiety disorder and panic disorder in adults: management. London: NICE; 2011 Jan. 41 p. Report No.:CG113</p>
</div>
</div>
</div>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [2]
                    </div>

                    <div class="column">
                      <div class="page" title="Page 12">
<div class="layoutArea">
<div class="column">
<p>Katzman MA, Bleau P, Blier P, Chokka P, Kjernisted K, Van Ameringen M. Canadian Anxiety Guidelines Initiative Group. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. BMC Psychiatry. 2014;14(Suppl 1):S1.</p>
</div>
</div>
</div>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [3]
                    </div>

                    <div class="column">
                      <div class="page" title="Page 12">
<div class="layoutArea">
<div class="column">
<p>Glass J, Lanctôt KL, Herrmann N, Sproule BA, Busto UE. Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. BMJ. 2005 Nov;331:1169.</p>
</div>
</div>
</div>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [4]
                    </div>

                    <div class="column">
                      <div class="page" title="Page 12">
<div class="layoutArea">
<div class="column">
<p>American Psychiatric Association (APA). Practice guideline for the treatment of patients with panic disorder [Internet]. 2010 [cited 2019 Jun 5].</p>
</div>
</div>
</div>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [5]
                    </div>

                    <div class="column">
                      <div class="page" title="Page 12">
<div class="layoutArea">
<div class="column">
<p>Alberta College of Family Physicians (ACFP). Benzodiazepines in generalized anxiety <span style="font-size: 1.5rem;">disorder: calm your nerves [Internet]. 2015 Apr 27 [cited 2019 Jun 5].</span></p>
</div>
</div>
</div>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [6]
                    </div>

                    <div class="column">
                      <div class="page" title="Page 12">
<div class="layoutArea">
<div class="column">
<p>Australian government: Department of Health. Effective treatments for panic disorder [Internet]. 2005 Jun [cited 2019 Jun 5].</p>
</div>
</div>
</div>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [7]
                    </div>

                    <div class="column">
                      <div class="page" title="Page 12">
<div class="layoutArea">
<div class="column">
<p>Pottie K, Thompson W, Davies S, Grenier J, Sadowski CA, Welch V et al. Deprescribing benzodiazepine receptor agonists: evidence-based clinical practice guideline. Can Fam Physician. 2018 May;64(5):339-51(Eng), e209-24 (Fr).</p>
</div>
</div>
</div>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [8]
                    </div>

                    <div class="column">
                      <div class="page" title="Page 12">
<div class="layoutArea">
<div class="column">
<p>Choosing Wisely Canada. Drowsy without feeling lousy [Internet]. 2017 [updated 2017 Jul; cited 2019 May 28].</p>
</div>
</div>
</div>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [9]
                    </div>

                    <div class="column">
                      <div class="page" title="Page 12">
<div class="layoutArea">
<div class="column">
<p><a href="https://link.cep.health/expertopinionrationale" data-wpel-link="external" target="_blank" rel="external noopener noreferrer">Expert opinion</a>.</p>
</div>
</div>
</div>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [10]
                    </div>

                    <div class="column">
                      <div class="page" title="Page 12">
<div class="layoutArea">
<div class="column">
<p>Sirdfield C, Chipchase SY, Owen S, Siriwardena AN. A systematic review and meta-synthesis of patients’ experiences and perceptions of seeking and using benzodiazepines and z-drugs: towards safer prescribing. Patient. 2017;10(1):1-15.</p>
</div>
</div>
</div>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [11]
                    </div>

                    <div class="column">
                      <div class="page" title="Page 12">
<div class="layoutArea">
<div class="column">
<p>Tannenbaum C. You may be at risk [Internet]. 2014 [cited 2019 May 31].</p>
</div>
</div>
</div>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [12]
                    </div>

                    <div class="column">
                      <div class="page" title="Page 12">
<div class="layoutArea">
<div class="column">
<p>College of Physicians and Surgeons of Alberta (CPSA). Benzodiazepines: use and taper [Internet]. 2016 [cited 2019 May 28].</p>
</div>
</div>
</div>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [13]
                    </div>

                    <div class="column">
                      <div class="page" title="Page 12">
<div class="layoutArea">
<div class="column">
<p>American Psychiatric Association (APA). Diagnostic and statistical manual of mental disorders. 5th ed. Washington, DC: APA; 2013.</p>
</div>
</div>
</div>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [14]
                    </div>

                    <div class="column">
                      <div class="page" title="Page 12">
<div class="layoutArea">
<div class="column">
<p>RxFiles. Geri-RxFiles: assessing medications in older adults. 3rd ed. Saskatoon: Saskatoon City Hospital; 2019.</p>
</div>
</div>
</div>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [15]
                    </div>

                    <div class="column">
                      <div class="page" title="Page 12">
<div class="layoutArea">
<div class="column">
<p>Pfizer ND. Welcome to the Patient Health Questionnaire (PHQ) screeners [Internet]. 2019 [cited 2019 May 31].</p>
</div>
</div>
</div>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [16]
                    </div>

                    <div class="column">
                      <div class="page" title="Page 12">
<div class="layoutArea">
<div class="column">
<p>Morin CM, Belleville G, Bélanger L, Ivers H. The Insomnia Severity Index: Psychometric indicators to detect insomnia cases and evaluate treatment response. Sleep. 2011 Jun;34(5):601–608.</p>
</div>
</div>
</div>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [17]
                    </div>

                    <div class="column">
                      <div class="page" title="Page 12">
<div class="layoutArea">
<div class="column">
<p>Siversten B, Omvik S, Pallesen S, Bjorvatn B, Havik OE, Kvale G et al. Cognitive behavioral therapy vs zopiclone for treatment of chronic primary insomnia in older adults: a randomized controlled trial. JAMA. 2006 Jun;295(24):2851-2858.</p>
</div>
</div>
</div>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [18]
                    </div>

                    <div class="column">
                      <div class="page" title="Page 12">
<div class="layoutArea">
<div class="column">
<p>Page AT, Clifford RM, Potter K, Schwartz D, Etherton-Beer CD. The feasibility and effect of deprescribing in older adults on mortality and health: a systematic review and meta- analysis. Br J Clin Pharmacol. 2016;82(3):583-623.</p>
</div>
</div>
</div>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [19]
                    </div>

                    <div class="column">
                      <div class="page" title="Page 12">
<div class="layoutArea">
<div class="column">
<p>Vissers FHJA, Knipschild PG, Crebolder HFJM. Is melatonin helpful in stopping the long-term use of hypnotics? A discontinuation trial. Pharm Word Sci. 2007 Dec;29(6):641-646.</p>
</div>
</div>
</div>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [20]
                    </div>

                    <div class="column">
                      <div class="page" title="Page 12">
<div class="layoutArea">
<div class="column">
<p>Voshaar RCO, Gorgels WJMJ, Mol AJJ, Van Balkom AJLM, Van de Lisdonk EH, Breteler MHM et al. Tapering off long-term benzodiazepine use with or without group cognitive-behavioural therapy: three-condition randomised controlled trial. Br J Psychiatry. 2003 Jun;182(6):498-504.</p>
</div>
</div>
</div>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [21]
                    </div>

                    <div class="column">
                      <div class="page" title="Page 12">
<div class="layoutArea">
<div class="column">
<p>Centre for Effective Practice (CEP). Management of chronic insomnia [Internet]. 2017 Jan 16 [cited 2019 May 31].</p>
</div>
</div>
</div>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [22]
                    </div>

                    <div class="column">
                      <div class="page" title="Page 12">
<div class="layoutArea">
<div class="column">
<p>Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005 Mar;53(4):695-9.</p>
</div>
</div>
</div>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [23]
                    </div>

                    <div class="column">
                      <div class="page" title="Page 12">
<div class="layoutArea">
<div class="column">
<p>Busto UE, Sykora K, Sellers EM. A clinical scale to assess benzodiazepine withdrawal. J Clin Psychopharmacol. 1989 Dec;9(6):412-6.</p>
</div>
</div>
</div>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [24]
                    </div>

                    <div class="column">
                      <div class="page" title="Page 12">
<div class="layoutArea">
<div class="column">
<p>Tyrer P, Murphy S, Riley P. The Benzodiazepine Withdrawal Symptom Questionnaire. J Affect Disord. 1990;19(1):53-61.</p>
</div>
</div>
</div>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [25]
                    </div>

                    <div class="column">
                      <div class="page" title="Page 12">
<div class="layoutArea">
<div class="column">
<p>World Health Organization (WHO). Clinical guidelines for withdrawal management and treatment of drug dependence in closed setting [Internet]. 2009 [cited 2019 Jun 5].</p>
</div>
</div>
</div>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [26]
                    </div>

                    <div class="column">
                      <div class="page" title="Page 12">
<div class="layoutArea">
<div class="column">
<p>Centre for Effective Practice (CEP). Opioid tapering template [Internet]. 2018 Feb [2019 Jun 5].</p>
</div>
</div>
</div>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [27]
                    </div>

                    <div class="column">
                      <div class="page" title="Page 12">
<div class="layoutArea">
<div class="column">
<p>Baandrup L, Ebdrup BH, Rasmussen JØ, Lindschou J, Gluud C, Glenthøj BY. Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users. Cochrane Database Syst Rev. 2018 Mar 15;3:CD011481.</p>
</div>
</div>
</div>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [28]
                    </div>

                    <div class="column">
                      <div class="page" title="Page 12">
<div class="layoutArea">
<div class="column">
<p>2019 American Geriatrics Society (AGS) Beers Criteria Update Expert Panel. American Geriatrics Society 2019 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2019;67:674-694.</p>
</div>
</div>
</div>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [29]
                    </div>

                    <div class="column">
                      <div class="page" title="Page 12">
<div class="layoutArea">
<div class="column">
<p>Toward Optimized Practice (TOP). Diagnosis to management guideline for adult primary insomnia. 2015 [cited 2019 Jun 14].</p>
</div>
</div>
</div>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [30]
                    </div>

                    <div class="column">
                      <div class="page" title="Page 12">
<div class="layoutArea">
<div class="column">
<p>Ontario Ministry of Health and Long-Term Care (MOHLTC). Formulary search [Internet]. 2018 Nov 8 [cited 2019 May 31].</p>
</div>
</div>
</div>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [31]
                    </div>

                    <div class="column">
                      <div class="page" title="Page 12">
<div class="layoutArea">
<div class="column">
<p>Canadian Pharmacists Association (CPhA). Compendium of pharmaceuticals and specialties: Benzodiazepine. 2015 [cited 2019 Jun 14].</p>
</div>
</div>
</div>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [32]
                    </div>

                    <div class="column">
                      <div class="page" title="Page 12">
<div class="layoutArea">
<div class="column">
<p>Busse, J. The 2017 Canadian guideline for opioids for chronic non-cancer pain [Internet]. 2017 [cited 2019 May 31].</p>
</div>
</div>
</div>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [33]
                    </div>

                    <div class="column">
                      <div class="page" title="Page 12">
<div class="layoutArea">
<div class="column">
<p>Participaction. Benefits and guidelines: older adults 65+ [Internet]. 2019 [cited 2019 Jun 5].</p>
</div>
</div>
</div>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [34]
                    </div>

                    <div class="column">
                      <div class="page" title="Page 12">
<div class="layoutArea">
<div class="column">
<p>Qaseem A, Kansagara D, Forciea M, Cooke M, Denberg T. Management of chronic insomnia disorder in adults: A clinical practice guideline from the American College of Physicians. Ann Intern Med. 2016;165(2):125-133.</p>
</div>
</div>
</div>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [35]
                    </div>

                    <div class="column">
                      <div class="page" title="Page 12">
<div class="layoutArea">
<div class="column">
<p>O’Mahony D, O’Sullivan D, Byrne S, O’Connor MN, Ryan C, Gallagher P. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing. 2015 Mar;44(2):213-8.</p>
</div>
</div>
</div>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [36]
                    </div>

                    <div class="column">
                      <div class="page" title="Page 12">
<div class="layoutArea">
<div class="column">
<p>Canadian Pharmacists Association (CPhA). Compendium of pharmaceuticals and specialties: Zopiclone CPhA monograph. 2019 Feb [cited 2019 Jun 14].</p>
</div>
</div>
</div>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [37]
                    </div>

                    <div class="column">
                      <div class="page" title="Page 12">
<div class="layoutArea">
<div class="column">
<p>Sanofi-Aventis Canada Inc. Product monograph: IvadalTM [Internet]. 2011 [cited 2019 Jun 5].</p>
</div>
</div>
</div>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [38]
                    </div>

                    <div class="column">
                      <div class="page" title="Page 12">
<div class="layoutArea">
<div class="column">
<p>Sanofi-Aventis Canada Inc. Product monograph: Imovane® [Internet]. 2018 [cited 2019 Jun 14].</p>
</div>
</div>
</div>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [39]
                    </div>

                    <div class="column">
                      <div class="page" title="Page 12">
<div class="layoutArea">
<div class="column">
<p>MOHLTC. Exceptional Access Program (EAP) reimbursement criteria for frequently requested drugs [Internet]. 2019 [updated 2019 Mar 1; cited 2019 Jun 5].</p>
</div>
</div>
</div>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [40]
                    </div>

                    <div class="column">
                      <div class="page" title="Page 12">
<div class="layoutArea">
<div class="column">
<p>MOHLTC. Applying to the EAP [Internet]. 2016 [updated 2019 Apr 30; cited 2019 Jun 5].</p>
</div>
</div>
</div>
                    </div>
                  </li>

               
                  <li class="columns is-flex is-gapless">
                    <div class="column is-1 is-1-mobile number">
                      [41]
                    </div>

                    <div class="column">
                      <div class="page" title="Page 12">
<div class="layoutArea">
<div class="column">
<p>United States Food and Drug Administration. Taking Z-drugs for insomnia? Know the risks [Internet]. 2019 Apr 30 [cited 2019 Jun 5].</p>
</div>
</div>
</div>
                    </div>
                  </li>

                            </ul>
           
</div>
</article>						</div>
					</div>
				</section>
							<section class="main-section" id="acknowledgement-and-legal" tabindex="-1">
					<div class="head">
						<div class="container">
							<h2 class="main-heading">
								Acknowledgement and legal								
							</h2>
							<div class="icon">
								<svg width="22" height="22" viewBox="0 0 22 22" fill="none" xmlns="http:/ /www.w3.org/2000/svg">
									<path fill-rule="evenodd" clip-rule="evenodd" d="M16 12H6V10H16V12Z" class="horizontal-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M10 16V6H12V16H10Z" class="vertical-stroke" />
									<path fill-rule="evenodd" clip-rule="evenodd" d="M11 20C15.9706 20 20 15.9706 20 11C20 6.02944 15.9706 2 11 2C6.02944 2 2 6.02944 2 11C2 15.9706 6.02944 20 11 20ZM11 22C17.0751 22 22 17.0751 22 11C22 4.92487 17.0751 0 11 0C4.92487 0 0 4.92487 0 11C0 17.0751 4.92487 22 11 22Z" class="outline" />
								</svg>
							</div>
						</div>
					</div>
					<div class="body">
						<div class="container">
							<article class="block--legal-text ">
<div class="container">
  <div class="columns is-gapless">
    <div class="column is-8 text">
      <div class="inner">
        <p>This Tool was developed as part of the Knowledge Translation in Primary Care Initiative, led by the Centre for Effective Practice in collaboration with the Ontario College of Family Physicians and the Nurse Practitioners’ Association of Ontario. Clinical leadership for the development of the Tool was provided by Dr. Mark Silverman CCFP and was subject to external review by health care providers and other relevant stakeholders. This Tool was funded by the Government of Ontario as part of the Knowledge Translation in Primary Care Initiative.</p>
<p>This Tool was developed for licensed health care professionals in Ontario as a guide only and does not constitute medical or other professional advice. Health care professionals are required to exercise their own clinical judgement in using this Tool. Neither the Centre for Effective Practice (“CEP”), Ontario College of Family Physicians, Nurse Practitioners’ Association of Ontario, Government of Ontario, nor any of their respective agents, appointees, directors, officers, employees, contractors, members or volunteers: (i) are providing medical, diagnostic or treatment services through this Tool; (ii) to the extent permitted by applicable law, accept any responsibility for the use or misuse of this Tool by any individual including, but not limited to, primary care providers or entity, including for any loss, damage or injury (including death) arising from or in connection with the use of this Tool, in whole or in part; or (iii) give or make any representation, warranty or endorsement of any external sources referenced in this Tool (whether specifically named or not) that are owned or operated by their parties, including any information or advice contained therein.</p>
<p>The Managing Benzodiazepine Use in Older Adults tool is a product of the Centre for Effective Practice. Permission to use, copy, and distribute this material is for all non-commercial and research purposes is granted, provided the above disclaimer, this paragraph and the following paragraphs, and appropriate citations appear in all copies, modifications, and distributions. Use of the Managing Benzodiazepine Use in Older Adults Tool for commercial purposes or any modifications of the Tool are subject to charge and must be negotiated with the Centre for Effective Practice (Email: info@cep.health).</p>
      </div>
    </div>
    <div class="column is-4 logos">
      <div class="inner">
                  <div>
            
                <p>
                  Developed by:                </p>

                
                  <img decoding="async" src="https://tools.cep.health/wp-content/uploads/2019/10/CEP-Logo-Color.svg" />

                
            
                <p>
                  In collaboration with:                </p>

                
                  <img decoding="async" src="https://tools.cep.health/wp-content/uploads/2020/02/OCFP_Logo_rgb_tagline.png" />

                
                  <img decoding="async" src="https://tools.cep.health/wp-content/uploads/2019/10/NPAO-Logo.svg" />

                
                      </div>
              </div>
    </div>
  </div>
</div>
</article>						</div>
					</div>
				</section>
			
		</section>
  </main>

<div class="utility-bar">
    <button data-search-tool-open class="utility-button search-button"><i class="icon icon-search"></i></button>
    <a href="#top-of-sections" class="utility-button back-to-top"><i class="icon icon-arrow-up"></i></a>
</div>
<div class="global-modal"></div>

<script type="speculationrules">
{"prefetch":[{"source":"document","where":{"and":[{"href_matches":"\/*"},{"not":{"href_matches":["\/wp-*.php","\/wp-admin\/*","\/wp-content\/uploads\/*","\/wp-content\/*","\/wp-content\/plugins\/*","\/wp-content\/themes\/cep-tools\/*","\/*\\?(.+)"]}},{"not":{"selector_matches":"a[rel~=\"nofollow\"]"}},{"not":{"selector_matches":".no-prefetch, .no-prefetch a"}}]},"eagerness":"conservative"}]}
</script>
<!-- This site is converting visitors into subscribers and customers with OptinMonster - https://optinmonster.com :: Campaign Title: Obesity management HTML - enhance confidence -->
<script>(function(d,u,ac){var s=d.createElement('script');s.type='text/javascript';s.src='https://a.omappapi.com/app/js/api.min.js';s.async=true;s.dataset.user=u;s.dataset.campaign=ac;d.getElementsByTagName('head')[0].appendChild(s);})(document,75076,'hhgajtyemrlknjsvrsd5');</script>
<!-- / OptinMonster --><!-- This site is converting visitors into subscribers and customers with OptinMonster - https://optinmonster.com :: Campaign Title: RSV HTML - change in patient care -->
<script>(function(d,u,ac){var s=d.createElement('script');s.type='text/javascript';s.src='https://a.omappapi.com/app/js/api.min.js';s.async=true;s.dataset.user=u;s.dataset.campaign=ac;d.getElementsByTagName('head')[0].appendChild(s);})(document,75076,'tkia37pcyyahx6opqim2');</script>
<!-- / OptinMonster --><!-- This site is converting visitors into subscribers and customers with OptinMonster - https://optinmonster.com :: Campaign Title: 2024.07 HTML Secure Messaging -->
<script>(function(d,u,ac){var s=d.createElement('script');s.type='text/javascript';s.src='https://a.omappapi.com/app/js/api.min.js';s.async=true;s.dataset.user=u;s.dataset.campaign=ac;d.getElementsByTagName('head')[0].appendChild(s);})(document,75076,'ngtztpck7tvpbcvakl7d');</script>
<!-- / OptinMonster --><!-- This site is converting visitors into subscribers and customers with OptinMonster - https://optinmonster.com :: Campaign Title: 2024.07 AI LC - fill knowledge gaps -->
<script>(function(d,u,ac){var s=d.createElement('script');s.type='text/javascript';s.src='https://a.omappapi.com/app/js/api.min.js';s.async=true;s.dataset.user=u;s.dataset.campaign=ac;d.getElementsByTagName('head')[0].appendChild(s);})(document,75076,'f2bzjhvjmeyfqkxxjggz');</script>
<!-- / OptinMonster --><!-- This site is converting visitors into subscribers and customers with OptinMonster - https://optinmonster.com :: Campaign Title: 2024.07 HTML Social Rxing -->
<script>(function(d,u,ac){var s=d.createElement('script');s.type='text/javascript';s.src='https://a.omappapi.com/app/js/api.min.js';s.async=true;s.dataset.user=u;s.dataset.campaign=ac;d.getElementsByTagName('head')[0].appendChild(s);})(document,75076,'qgchslypk4toxdtgsfsf');</script>
<!-- / OptinMonster --><!-- This site is converting visitors into subscribers and customers with OptinMonster - https://optinmonster.com :: Campaign Title: 2024.07 HTML COPD -->
<script>(function(d,u,ac){var s=d.createElement('script');s.type='text/javascript';s.src='https://a.omappapi.com/app/js/api.min.js';s.async=true;s.dataset.user=u;s.dataset.campaign=ac;d.getElementsByTagName('head')[0].appendChild(s);})(document,75076,'cfontzigzdapzyxtbhg4');</script>
<!-- / OptinMonster --><!-- This site is converting visitors into subscribers and customers with OptinMonster - https://optinmonster.com :: Campaign Title: 2024.07 HTML Type 2 DM Insulin -->
<script>(function(d,u,ac){var s=d.createElement('script');s.type='text/javascript';s.src='https://a.omappapi.com/app/js/api.min.js';s.async=true;s.dataset.user=u;s.dataset.campaign=ac;d.getElementsByTagName('head')[0].appendChild(s);})(document,75076,'nflzw9az1mcray2ltc4m');</script>
<!-- / OptinMonster --><!-- This site is converting visitors into subscribers and customers with OptinMonster - https://optinmonster.com :: Campaign Title: 2024.07 HTML Type 2 DM Non-Insulin -->
<script>(function(d,u,ac){var s=d.createElement('script');s.type='text/javascript';s.src='https://a.omappapi.com/app/js/api.min.js';s.async=true;s.dataset.user=u;s.dataset.campaign=ac;d.getElementsByTagName('head')[0].appendChild(s);})(document,75076,'edlo1w0s0lujgciyjgf9');</script>
<!-- / OptinMonster --><!-- This site is converting visitors into subscribers and customers with OptinMonster - https://optinmonster.com :: Campaign Title: 2024.07 HTML ME/CFS -->
<script>(function(d,u,ac){var s=d.createElement('script');s.type='text/javascript';s.src='https://a.omappapi.com/app/js/api.min.js';s.async=true;s.dataset.user=u;s.dataset.campaign=ac;d.getElementsByTagName('head')[0].appendChild(s);})(document,75076,'ybbyul2ujyofvsznkiti');</script>
<!-- / OptinMonster --><!-- This site is converting visitors into subscribers and customers with OptinMonster - https://optinmonster.com :: Campaign Title: 2024.07 HTML FM -->
<script>(function(d,u,ac){var s=d.createElement('script');s.type='text/javascript';s.src='https://a.omappapi.com/app/js/api.min.js';s.async=true;s.dataset.user=u;s.dataset.campaign=ac;d.getElementsByTagName('head')[0].appendChild(s);})(document,75076,'doewskxay35gb860nodl');</script>
<!-- / OptinMonster --><!-- This site is converting visitors into subscribers and customers with OptinMonster - https://optinmonster.com :: Campaign Title: 2024.07 HTML Role Q -->
<script>(function(d,u,ac){var s=d.createElement('script');s.type='text/javascript';s.src='https://a.omappapi.com/app/js/api.min.js';s.async=true;s.dataset.user=u;s.dataset.campaign=ac;d.getElementsByTagName('head')[0].appendChild(s);})(document,75076,'wm0xaeyycxvhthxjz76n');</script>
<!-- / OptinMonster --><!-- This site is converting visitors into subscribers and customers with OptinMonster - https://optinmonster.com :: Campaign Title: 2024.07 HTML POTS -->
<script>(function(d,u,ac){var s=d.createElement('script');s.type='text/javascript';s.src='https://a.omappapi.com/app/js/api.min.js';s.async=true;s.dataset.user=u;s.dataset.campaign=ac;d.getElementsByTagName('head')[0].appendChild(s);})(document,75076,'iqff27bs0pszfabitkgw');</script>
<!-- / OptinMonster --><!-- This site is converting visitors into subscribers and customers with OptinMonster - https://optinmonster.com :: Campaign Title: 2024.07 HTML HF -->
<script>(function(d,u,ac){var s=d.createElement('script');s.type='text/javascript';s.src='https://a.omappapi.com/app/js/api.min.js';s.async=true;s.dataset.user=u;s.dataset.campaign=ac;d.getElementsByTagName('head')[0].appendChild(s);})(document,75076,'xfup8pda84l5bd0udyje');</script>
<!-- / OptinMonster --><!-- This site is converting visitors into subscribers and customers with OptinMonster - https://optinmonster.com :: Campaign Title: 2024.07 HTML A&D -->
<script>(function(d,u,ac){var s=d.createElement('script');s.type='text/javascript';s.src='https://a.omappapi.com/app/js/api.min.js';s.async=true;s.dataset.user=u;s.dataset.campaign=ac;d.getElementsByTagName('head')[0].appendChild(s);})(document,75076,'xokl1h6esysgo5wdkq9d');</script>
<!-- / OptinMonster --><!-- This site is converting visitors into subscribers and customers with OptinMonster - https://optinmonster.com :: Campaign Title: 2022.11 E2P Patient Resource Page -->
<script>(function(d,u,ac){var s=d.createElement('script');s.type='text/javascript';s.src='https://a.omappapi.com/app/js/api.min.js';s.async=true;s.dataset.user=u;s.dataset.campaign=ac;d.getElementsByTagName('head')[0].appendChild(s);})(document,75076,'jaxkt0icjnuu0z43iuik');</script>
<!-- / OptinMonster --><!-- This site is converting visitors into subscribers and customers with OptinMonster - https://optinmonster.com :: Campaign Title: 2021.11 MAID - Measuring knowledge -->
<script>(function(d,u,ac){var s=d.createElement('script');s.type='text/javascript';s.src='https://a.omappapi.com/app/js/api.min.js';s.async=true;s.dataset.user=u;s.dataset.campaign=ac;d.getElementsByTagName('head')[0].appendChild(s);})(document,75076,'vso3vlstnsfjgeuogzry');</script>
<!-- / OptinMonster --><!-- This site is converting visitors into subscribers and customers with OptinMonster - https://optinmonster.com :: Campaign Title: 2021.11 Fall Prevention & MGMT Resource - Fill knowledge gaps -->
<script>(function(d,u,ac){var s=d.createElement('script');s.type='text/javascript';s.src='https://a.omappapi.com/app/js/api.min.js';s.async=true;s.dataset.user=u;s.dataset.campaign=ac;d.getElementsByTagName('head')[0].appendChild(s);})(document,75076,'awihu5noxqqj5s7iasv8');</script>
<!-- / OptinMonster --><!-- This site is converting visitors into subscribers and customers with OptinMonster - https://optinmonster.com :: Campaign Title: 2021.08 PPIs - Change prescribing -->
<script>(function(d,u,ac){var s=d.createElement('script');s.type='text/javascript';s.src='https://a.omappapi.com/app/js/api.min.js';s.async=true;s.dataset.user=u;s.dataset.campaign=ac;d.getElementsByTagName('head')[0].appendChild(s);})(document,75076,'cdikvvptidch9oj1o56k');</script>
<!-- / OptinMonster --><!-- This site is converting visitors into subscribers and customers with OptinMonster - https://optinmonster.com :: Campaign Title: 2021.08 Chronic Insomnia HTML - Increase Confidence -->
<script>(function(d,u,ac){var s=d.createElement('script');s.type='text/javascript';s.src='https://a.omappapi.com/app/js/api.min.js';s.async=true;s.dataset.user=u;s.dataset.campaign=ac;d.getElementsByTagName('head')[0].appendChild(s);})(document,75076,'qeu7gqedkzjnotzskhln');</script>
<!-- / OptinMonster --><!-- This site is converting visitors into subscribers and customers with OptinMonster - https://optinmonster.com :: Campaign Title: 2021.08 Non-Medical Cannabis Resource - Fill knowledge gaps -->
<script>(function(d,u,ac){var s=d.createElement('script');s.type='text/javascript';s.src='https://a.omappapi.com/app/js/api.min.js';s.async=true;s.dataset.user=u;s.dataset.campaign=ac;d.getElementsByTagName('head')[0].appendChild(s);})(document,75076,'okkbvdzprjjylm7wjkhe');</script>
<!-- / OptinMonster --><!-- This site is converting visitors into subscribers and customers with OptinMonster - https://optinmonster.com :: Campaign Title: 2021.07 ADHD Resource - Fill knowledge gaps -->
<script>(function(d,u,ac){var s=d.createElement('script');s.type='text/javascript';s.src='https://a.omappapi.com/app/js/api.min.js';s.async=true;s.dataset.user=u;s.dataset.campaign=ac;d.getElementsByTagName('head')[0].appendChild(s);})(document,75076,'rxekv8i4pwnmp4zvclcm');</script>
<!-- / OptinMonster --><!-- This site is converting visitors into subscribers and customers with OptinMonster - https://optinmonster.com :: Campaign Title: 2020.05 COVID-19 - Change the way you will provide care for your patients? -->
<script>(function(d,u,ac){var s=d.createElement('script');s.type='text/javascript';s.src='https://a.omappapi.com/app/js/api.min.js';s.async=true;s.dataset.user=u;s.dataset.campaign=ac;d.getElementsByTagName('head')[0].appendChild(s);})(document,75076,'koz3ranojk5yi8c5wmpe');</script>
<!-- / OptinMonster --><!-- This site is converting visitors into subscribers and customers with OptinMonster - https://optinmonster.com :: Campaign Title: 2020.07 CNCP - change in patient care -->
<script>(function(d,u,ac){var s=d.createElement('script');s.type='text/javascript';s.src='https://a.omappapi.com/app/js/api.min.js';s.async=true;s.dataset.user=u;s.dataset.campaign=ac;d.getElementsByTagName('head')[0].appendChild(s);})(document,75076,'e6m4njfonyv93sqcttlx');</script>
<!-- / OptinMonster -->		<!-- Google Tag Manager (noscript) snippet added by Site Kit -->
		<noscript>
			<iframe src="https://www.googletagmanager.com/ns.html?id=GTM-WLFDZV" height="0" width="0" style="display:none;visibility:hidden"></iframe>
		</noscript>
		<!-- End Google Tag Manager (noscript) snippet added by Site Kit -->
				<script type="text/javascript">
		var hhgajtyemrlknjsvrsd5_shortcode = true;var tkia37pcyyahx6opqim2_shortcode = true;var ngtztpck7tvpbcvakl7d_shortcode = true;var f2bzjhvjmeyfqkxxjggz_shortcode = true;var qgchslypk4toxdtgsfsf_shortcode = true;var cfontzigzdapzyxtbhg4_shortcode = true;var nflzw9az1mcray2ltc4m_shortcode = true;var edlo1w0s0lujgciyjgf9_shortcode = true;var ybbyul2ujyofvsznkiti_shortcode = true;var doewskxay35gb860nodl_shortcode = true;var wm0xaeyycxvhthxjz76n_shortcode = true;var iqff27bs0pszfabitkgw_shortcode = true;var xfup8pda84l5bd0udyje_shortcode = true;var xokl1h6esysgo5wdkq9d_shortcode = true;var jaxkt0icjnuu0z43iuik_shortcode = true;var vso3vlstnsfjgeuogzry_shortcode = true;var awihu5noxqqj5s7iasv8_shortcode = true;var cdikvvptidch9oj1o56k_shortcode = true;var qeu7gqedkzjnotzskhln_shortcode = true;var okkbvdzprjjylm7wjkhe_shortcode = true;var rxekv8i4pwnmp4zvclcm_shortcode = true;var koz3ranojk5yi8c5wmpe_shortcode = true;var e6m4njfonyv93sqcttlx_shortcode = true;		</script>
		<style id='core-block-supports-inline-css' type='text/css'>
.wp-container-core-columns-is-layout-9d6595d7{flex-wrap:nowrap;}
</style>
<script>(function(d){var s=d.createElement("script");s.type="text/javascript";s.src="https://a.omappapi.com/app/js/api.min.js";s.async=true;s.id="omapi-script";d.getElementsByTagName("head")[0].appendChild(s);})(document);</script><script type="text/javascript" src="https://tools.cep.health/wp-content/themes/cep-tools/js/vendor.min.js" id="vendor-js"></script>
<script type="text/javascript" src="https://tools.cep.health/wp-content/themes/cep-tools/js/app.min.js?ver=1674670088" id="app-js"></script>
<script type="text/javascript" src="https://tools.cep.health/wp-content/plugins/glossary-by-codeat/assets/js/off-screen.js?ver=2.3.5" id="glossary-off-screen-js"></script>
<script type="text/javascript" src="https://tools.cep.health/wp-content/themes/cep-tools/assets/js/app/modules/slider.js?ver=6.4.2" id="block-acf-drug-options-js"></script>
<script type="text/javascript" src="https://tools.cep.health/wp-content/plugins/optinmonster/assets/dist/js/helper.min.js?ver=2.16.20" id="optinmonster-wp-helper-js"></script>
		<script type="text/javascript">var omapi_localized = {
			ajax: 'https://tools.cep.health/wp-admin/admin-ajax.php?optin-monster-ajax-route=1',
			nonce: '54d7109d0e',
			slugs:
			{"hhgajtyemrlknjsvrsd5":{"slug":"hhgajtyemrlknjsvrsd5","mailpoet":false},"tkia37pcyyahx6opqim2":{"slug":"tkia37pcyyahx6opqim2","mailpoet":false},"ngtztpck7tvpbcvakl7d":{"slug":"ngtztpck7tvpbcvakl7d","mailpoet":false},"f2bzjhvjmeyfqkxxjggz":{"slug":"f2bzjhvjmeyfqkxxjggz","mailpoet":false},"qgchslypk4toxdtgsfsf":{"slug":"qgchslypk4toxdtgsfsf","mailpoet":false},"cfontzigzdapzyxtbhg4":{"slug":"cfontzigzdapzyxtbhg4","mailpoet":false},"nflzw9az1mcray2ltc4m":{"slug":"nflzw9az1mcray2ltc4m","mailpoet":false},"edlo1w0s0lujgciyjgf9":{"slug":"edlo1w0s0lujgciyjgf9","mailpoet":false},"ybbyul2ujyofvsznkiti":{"slug":"ybbyul2ujyofvsznkiti","mailpoet":false},"doewskxay35gb860nodl":{"slug":"doewskxay35gb860nodl","mailpoet":false},"wm0xaeyycxvhthxjz76n":{"slug":"wm0xaeyycxvhthxjz76n","mailpoet":false},"iqff27bs0pszfabitkgw":{"slug":"iqff27bs0pszfabitkgw","mailpoet":false},"xfup8pda84l5bd0udyje":{"slug":"xfup8pda84l5bd0udyje","mailpoet":false},"xokl1h6esysgo5wdkq9d":{"slug":"xokl1h6esysgo5wdkq9d","mailpoet":false},"jaxkt0icjnuu0z43iuik":{"slug":"jaxkt0icjnuu0z43iuik","mailpoet":false},"vso3vlstnsfjgeuogzry":{"slug":"vso3vlstnsfjgeuogzry","mailpoet":false},"awihu5noxqqj5s7iasv8":{"slug":"awihu5noxqqj5s7iasv8","mailpoet":false},"cdikvvptidch9oj1o56k":{"slug":"cdikvvptidch9oj1o56k","mailpoet":false},"qeu7gqedkzjnotzskhln":{"slug":"qeu7gqedkzjnotzskhln","mailpoet":false},"okkbvdzprjjylm7wjkhe":{"slug":"okkbvdzprjjylm7wjkhe","mailpoet":false},"rxekv8i4pwnmp4zvclcm":{"slug":"rxekv8i4pwnmp4zvclcm","mailpoet":false},"koz3ranojk5yi8c5wmpe":{"slug":"koz3ranojk5yi8c5wmpe","mailpoet":false},"e6m4njfonyv93sqcttlx":{"slug":"e6m4njfonyv93sqcttlx","mailpoet":false}}		};</script>
				<script type="text/javascript">var omapi_data = {"object_id":12552,"object_key":"tools","object_type":"post","term_ids":[],"wp_json":"https:\/\/tools.cep.health\/wp-json","wc_active":false,"edd_active":false,"nonce":"9051981ff5"};</script>
		
  </body>
</html>
